US20130142863A1 - Phosphatidylcholine lipid liposomes as boundry lubricants in aqueous media - Google Patents
Phosphatidylcholine lipid liposomes as boundry lubricants in aqueous media Download PDFInfo
- Publication number
- US20130142863A1 US20130142863A1 US13/704,866 US201113704866A US2013142863A1 US 20130142863 A1 US20130142863 A1 US 20130142863A1 US 201113704866 A US201113704866 A US 201113704866A US 2013142863 A1 US2013142863 A1 US 2013142863A1
- Authority
- US
- United States
- Prior art keywords
- liposomes
- gel
- phase
- lubrication
- hspc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 210
- 239000000314 lubricant Substances 0.000 title claims description 24
- 239000012736 aqueous medium Substances 0.000 title claims description 18
- -1 Phosphatidylcholine lipid Chemical class 0.000 title description 4
- 238000005461 lubrication Methods 0.000 claims abstract description 77
- 238000000034 method Methods 0.000 claims abstract description 43
- 230000007704 transition Effects 0.000 claims abstract description 26
- 230000001050 lubricating effect Effects 0.000 claims abstract description 15
- 208000036487 Arthropathies Diseases 0.000 claims abstract description 8
- 150000002632 lipids Chemical class 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 31
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 26
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims description 17
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 claims description 14
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims description 14
- 125000002525 phosphocholine group Chemical group OP(=O)(OCC[N+](C)(C)C)O* 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000000243 solution Substances 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 8
- 239000002691 unilamellar liposome Substances 0.000 claims description 8
- 210000000281 joint capsule Anatomy 0.000 claims description 7
- 239000001294 propane Substances 0.000 claims description 7
- 150000008105 phosphatidylcholines Chemical class 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 150000002430 hydrocarbons Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- DDBRXOJCLVGHLX-UHFFFAOYSA-N n,n-dimethylmethanamine;propane Chemical compound CCC.CN(C)C DDBRXOJCLVGHLX-UHFFFAOYSA-N 0.000 claims 2
- ZUHZZVMEUAUWHY-UHFFFAOYSA-N n,n-dimethylpropan-1-amine Chemical compound CCCN(C)C ZUHZZVMEUAUWHY-UHFFFAOYSA-N 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 71
- 239000010445 mica Substances 0.000 description 66
- 229910052618 mica group Inorganic materials 0.000 description 66
- 239000012071 phase Substances 0.000 description 54
- 238000013459 approach Methods 0.000 description 28
- 239000007787 solid Substances 0.000 description 26
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 23
- 238000000926 separation method Methods 0.000 description 20
- 210000000845 cartilage Anatomy 0.000 description 15
- 238000005259 measurement Methods 0.000 description 15
- 235000010469 Glycine max Nutrition 0.000 description 14
- 238000002474 experimental method Methods 0.000 description 13
- 239000002202 Polyethylene glycol Substances 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 150000003904 phospholipids Chemical class 0.000 description 12
- 229920001223 polyethylene glycol Polymers 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 239000004417 polycarbonate Substances 0.000 description 11
- 230000000052 comparative effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000000576 coating method Methods 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000012512 characterization method Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000002296 dynamic light scattering Methods 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000000418 atomic force spectrum Methods 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 210000001503 joint Anatomy 0.000 description 6
- 229920000515 polycarbonate Polymers 0.000 description 6
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000001188 articular cartilage Anatomy 0.000 description 4
- 125000002091 cationic group Chemical group 0.000 description 4
- 230000000887 hydrating effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 238000001878 scanning electron micrograph Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000008365 aqueous carrier Substances 0.000 description 3
- 238000004630 atomic force microscopy Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000003841 chloride salts Chemical class 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 210000001624 hip Anatomy 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- SUHOQUVVVLNYQR-MRVPVSSYSA-O glycerylphosphorylcholine Chemical compound C[N+](C)(C)CCO[P@](O)(=O)OC[C@H](O)CO SUHOQUVVVLNYQR-MRVPVSSYSA-O 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000001179 synovial fluid Anatomy 0.000 description 2
- 210000001738 temporomandibular joint Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- WTJKGGKOPKCXLL-VYOBOKEXSA-N 1-hexadecanoyl-2-(9Z-octadecenoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC WTJKGGKOPKCXLL-VYOBOKEXSA-N 0.000 description 1
- NTTZBBIBMSBLNK-UHFFFAOYSA-M 2,3-di(octadecanoyloxy)propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NTTZBBIBMSBLNK-UHFFFAOYSA-M 0.000 description 1
- IGKWQNBUDQUOJB-UHFFFAOYSA-N 2,3-di(tetradecanoyloxy)propyl-trimethylazanium Chemical compound CCCCCCCCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC IGKWQNBUDQUOJB-UHFFFAOYSA-N 0.000 description 1
- YHHSONZFOIEMCP-UHFFFAOYSA-N 2-(trimethylazaniumyl)ethyl hydrogen phosphate Chemical group C[N+](C)(C)CCOP(O)([O-])=O YHHSONZFOIEMCP-UHFFFAOYSA-N 0.000 description 1
- 208000025978 Athletic injury Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 229920001651 Cyanoacrylate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 1
- 229910052581 Si3N4 Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041738 Sports injury Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- JLPULHDHAOZNQI-JLOPVYAASA-N [(2r)-3-hexadecanoyloxy-2-[(9e,12e)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC JLPULHDHAOZNQI-JLOPVYAASA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000001520 comb Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005421 electrostatic potential Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000011540 hip replacement Methods 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000013150 knee replacement Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010079 rubber tapping Methods 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002832 shoulder Anatomy 0.000 description 1
- HQVNEWCFYHHQES-UHFFFAOYSA-N silicon nitride Chemical compound N12[Si]34N5[Si]62N3[Si]51N64 HQVNEWCFYHHQES-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/10—Materials for lubricating medical devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/24—Materials or treatment for tissue regeneration for joint reconstruction
Definitions
- Liposomes are vesicles whose membranes in most cases are based on phospholipid bilayers. They are generally biocompatible and, when modified with other molecules, are widely used in clinical applications, primarily as drug delivery vehicles, as well as in gene therapy and for diagnostic imaging.
- WO 08/038,292 by some of the present inventors, disclosed, inter alia, multilamellar vesicles (MLVs) of several phospholipids above their liquid-crystalline-phase to gel-phase transition temperature Tm as possible boundary lubricants in the articular cartilage environment.
- MLVs multilamellar vesicles
- Boundary lubrication in aqueous media is often problematic as water on its own is not a good lubricant, while common surfaces or surface coatings in water frequently exhibit quite high friction (with friction coefficients ⁇ >0.01-0.05), especially at high pressures.
- U.S. Pat. No. 6,800,298 describes a lubricant composition comprising dextran-based hydrogel with lipids.
- gel-phase liposomes are known to transform from their gel (solid) phase to liquid crystalline phase at a characteristic temperature designated T m , defined as the temperature at which the maximal change in the excess heat capacity (kcal/mol/deg) occurs.
- T m characteristic temperature
- the lubrication properties of gel phase liposomes, namely, liposomes applied onto surfaces at a temperature which is lower than their T m were tested and were found to be particularly good. It has been found that gel-phase liposomes are especially useful for lubricating surfaces that are subject to high pressure, up to 120 atmospheres (around 120 MPa) or more.
- the gel-phase liposomes may be used according to the invention for the treatment of joint dysfunction, wherein the pressure within the joint reaches values in the range of 30 to 120 atmospheres (3-12 MPa). Characteristic pressures in joints are reported in the following references:
- gel-phase liposomes of different compositions and size characteristics can provide efficient lubrication in aqueous environments on solid surfaces on which they spontaneously adsorb to form surface coatings.
- the lubrication yielding, in most cases, values ⁇ ca. 1 ⁇ 10 ⁇ 3 ) occurs under pressures of up to 120 atmospheres or more, and down to very low sliding velocities, with little apparent wear of the liposome surface coatings.
- the invention provides a method for lubricating one or more non-biological surfaces (in particular negatively charged solid surfaces), comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature T m of said liposomes.
- the invention also provides a method for lubricating one or more surfaces of a biological tissue in a mammalian subject (for example, a cartilage surface within a joint capsule), comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature T m of said liposomes.
- a mammalian subject for example, a cartilage surface within a joint capsule
- the use of gel-phase liposomes for lubricating surfaces having a surface temperature which is below the phase transition temperature T m of said liposomes constitutes another aspect of the invention.
- the invention also encompasses a therapeutic composition for lubricating the surface of a biological tissue in a mammalian subject, wherein said composition comprises gel-phase liposomes and an aqueous carrier.
- the invention provides the use of gel-phase liposomes in the preparation of a therapeutic composition for the treatment of joint dysfunction in a mammalian subject by means of the lubrication of cartilage surface(s) within the joint capsule, wherein the temperature of said surfaces at the time of lubrication is below the phase transition temperature T m of said liposomes.
- the invention also provides gel-phase liposomes for the treatment of joint dysfunction in a mammalian subject by means of the lubrication of surface(s) within the joint capsule, wherein the temperature of said surfaces at the time of lubrication is below the phase transition temperature T m of said liposomes.
- the maximal pressure within the joint is in the range of 30 to 120 atmospheres (3-12 MPa).
- the carrier used for administering the liposomes to the mammalian subject is preferably an aqueous carrier (e.g., an aqueous-based buffer solution) free of organic co-solvents or extraneous organic compounds (other than of course the liposomes).
- an aqueous carrier e.g., an aqueous-based buffer solution
- organic co-solvents or extraneous organic compounds other than of course the liposomes.
- Gel-phase Liposomes to be used according to the invention are based on phosphocholine-containing lipids and mixtures thereof. However, it is possible to combine lipids having polar head groups other than phosphocholine in the gel-phase liposomes.
- Liposomes operable in the invention have external (exposed at the outer liposome surface) polar head groups which are composed of at least 95 mole % phosphocholine groups, and of up to 5 mole % external non-phosphocholine head group having an unperturbed-end-to-end radius in aqueous medium equal to or smaller than about 1 nm, or cross-section parameter which is less than 0.8 nm 2 , (provided, of course that said liposomes are in their gel-phase and have a T m which is higher than the intended working temperature).
- liposomes in which the up to 5 mole % external non-phosphocholine head group units have an unperturbed-end-to-end radius (in the aqueous medium) which is larger than about 1 nm are not suitable for use as lubricant compositions since the systems formed by incubating the solid surfaces therein have a high friction coefficient.
- liposomes in which the 5% of external non-phosphocholine head groups were the PEG groups of DSPE-PEG2000, having an unperturbed-end-to-end radius (in aqueous medium) of about 4 nm demonstrated poor lubrication properties, having friction coefficients of 0.05 to 0.1 (Example C7, see below).
- head groups other than phosphocholine units in the gel-phase liposomes is permitted, provided that the unperturbed-end-to-end radius of said non-phosphocholine groups is less than 1 nm, or their cross section is less than 0.8 nm 2 .
- unperturbed-end-to-end radius means the steric size of said head group when it is not subject to external constraints, and is used herein in order to estimate the radius of non-phosphocholine head groups which are polymer chains (such as PEG chain in the case of DSPE-PEG2000 lipid) and also for non-phosphocholine head groups which are molecular/cationic entities (such as the TAP group in the 1,2-dimyristoyl-3-trimethylammonium-propane (DMATP)).
- non-phosphocholine head groups which are polymer chains (such as PEG chain in the case of DSPE-PEG2000 lipid) and also for non-phosphocholine head groups which are molecular/cationic entities (such as the TAP group in the 1,2-dimyristoyl-3-trimethylammonium-propane (DMATP)
- the size of the charged head-group on the DMTAP is approximately 0.3-0.5 nm and its radius would be about half of that, say 0.2 nm.
- lipids which contain the TAP head group (and two hydrocarbon saturated chains) can be combined with phosphocholine-containing lipids to form liposomes which are suitable for use in the invention.
- thermodynamic phase behavior of cationic lipids calorimetric, infrared spectroscopic and X-ray diffraction studies of lipid bilayer membranes composed of 1,2-di-O-myristoyl-3-N,N,N-trimethylaminopropane (DM-TAP). Biochim. Biophys. Acta. 1510:70-82, 2001].
- the gel-phase liposomes used according to the invention comprise one or more phosphatidylcholine lipids, with the T m values of the liposomes being not less than 40° C., preferably not less than 45° C.
- Mixtures of different phosphatidylcholine lipids can be used to form the liposomes, with the molar ratio between the components of the mixture being adjusted to produce liposomes having the desired T m value [see Scott et al., Biophysical Journal (28), p. 117-132 (1979)].
- T m is not less than 50° C., e.g., from 50 to 60° C.
- the hydrocarbon tails of the phosphatidylcholine lipids are saturated and contain not less than 17 carbon atoms.
- liposomes comprising hydrogenated soy phosphatidylcholine (HSPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and dipalmitoylphosphatidylcholine (DPPC) and mixtures thereof may act as efficient lubricants in aqueous media even at physiologically high pressures of up to 120 atmospheres (85% of the HSPC are DSPC and 15% are the sum of 1 stearoyl 2-palmitoyl PC plus 1-palmitoyl 2-steroyl PC).
- T m values for HSPC, DSPC and DPPC are 52.5° C., 55° C. and 41.4° C., respectively.
- T m values of various PC-based lipids may be found in “Thermotropic Phase Transitions of Pure Lipids in Model Membranes and Their Modifications by Membrane Proteins”, John R. Silvius, Lipid-Protein Interactions, John Wiley & Sons, Inc., New York, 1982, and also in the Lipid Thermotropic Phase Transition Data Base—LIPIDA.
- the liposomes to be used are in the form of small unilamellar vesicles (SUV).
- SUV small unilamellar vesicles
- HSPC hydrogenated soy phosphatidylcholine
- the SUV liposomes have a mean diameter which is smaller than 100 nm.
- At least 95% of the external polar head groups of the gel-phase liposomes used in the method of the invention are phosphoryl choline head group, the liposomes being in the SUV form and having a mean diameter which is smaller than 100 nm.
- these gel-phase SUV PC-based liposomes have a mean diameter ranging from about 60 nm to about 80 nm, more preferably ranging from about 65 nm to about 75 nm.
- the liposomes in the compositions described herein are in the form of multilamellar vesicles (MLVs).
- MLVs multilamellar vesicles
- these liposomes have a mean diameter larger than 200 nm, yet more preferably larger than 500 nm, and most preferably of about 1 micron and larger.
- Preferred liposomes to be used according to the invention for example for lubricating non-biological surfaces, consist of HSPC, DSPC or DPPC lipids. These PC-based liposomes exhibit good to excellent lubrication results under various conditions, as can be seen in Examples S1, S2, S3, S6, S10 and S11.
- Another class of preferred liposomes to be used according to the invention is based on a mixture comprising a first lipid, which is phosphocholine-containing lipid (e.g., HSPC, DSPC or DPPC, or their mixtures) and a second lipid, which contains TAP hydrophilic head group, wherein the mole ratio between said first and second lipids is from 95:5 to 99.9:0.1.
- the second lipid namely, the TAP-containing lipid has two hydrocarbon chains which independently contain 14, 16 or 18 carbon atoms.
- the TAP-containing liposome is selected from the group consisting of 1,2-ditetradecanoyl-3-trimethylammonium-propane (DMTAP), 1,2-dipalmitoyl-3-dimethylammonium-propane and 1,2-disteraroyl-3-dimethylammonium-propane, which are also described as 14:0 TAP, 16:0 TAP and 18:0 TAP, respectively, indicating that the length of both chains of the lipid is the same (being 14, 16 and 18, respectively).
- DMTAP 1,2-ditetradecanoyl-3-trimethylammonium-propane
- 1,2-dipalmitoyl-3-dimethylammonium-propane 1,2-disteraroyl-3-dimethylammonium-propane
- the good lubrication was obtained also when the surface of the liposomes was positively charged (for example, when some of the zwiterionic HSPC molecules were replaced by charged DMTAP cationic lipids).
- liposomes having positively charged surface showed improved lubrication with the negatively-charged solid surfaces in water at high salt concentrations (for example, not less than 0.05M of a 1:1 salt, e.g., not less than 0.15M), as compared to liposomes having positively charged surface used in water containing no added salt.
- the gel-phase liposomes to be used have positively charged surfaces.
- the liposomes used according to the present invention adsorb spontaneously onto negatively charged solid surfaces in water, to form close-packed boundary layers that provided uniquely efficient lubrication, resulting in friction coefficients down to 2 ⁇ 10 ⁇ 5 at pressures of more than 100 atmospheres (above 10 MPa). This extremely low friction at such high pressures makes these liposomes extremely suitable for providing efficient lubrication in aqueous media.
- the surfaces to be treated by the liposomes in accordance with the invention may be overall neutral, but having discrete positive and negative regions, such that the liposomes attach to the negatively-charged regions, or even to overall-positively charged surfaces if there are also negatively charged patches on them onto which the liposomes may attach.
- Positively-charged surfaces can also be treated with gel-phase phosphatidylcholine liposomes with up to 5 mole % of negatively-charged lipids such as phosphatidic acid (PA), phopsphatidyl glycerol (PG), phopsphatidyl inositil (PI) and phosphatidylserine (PS).
- PA phosphatidic acid
- PG phopsphatidyl glycerol
- PI phopsphatidyl inositil
- PS phosphatidylserine
- a lubricant system comprising a plurality of liposomes being in their gel-phase and further being spontaneously adsorbed on at least one of two negatively charged solid surfaces, in an aqueous medium.
- the characteristics of the liposomes are as set forth above.
- Suitable negatively charged solid surfaces include, but are not limited to, glass, mica and cartilage.
- the gel-phase liposomes to be used according to the invention proved as efficient lubricants when coated on one or two mica surfaces, having friction coefficients lower than 1 ⁇ 10 ⁇ 2 and even lower than 5 ⁇ 10 ⁇ 3 and 15 ⁇ 10 ⁇ 4 .
- the lubricant system described herein has a coefficient of sliding friction between the above-described surfaces which is less than about 1 ⁇ 10 ⁇ 2 under a pressure of at least 1 Mpa, in the aqueous medium.
- liposomes described herein may reduce friction between surfaces onto which they spontaneously adsorb, up to the maximal pressures pertaining in mammalian joints, to levels that are even lower than between healthy sliding articular cartilage. Such low friction between surfaces in aqueous media at these high pressures has not hitherto been attained by any physically-attached boundary lubricant system.
- a method of decreasing the friction coefficient between two negatively charged solid surfaces in aqueous medium to below about 1 ⁇ 10 ⁇ 2 under a pressure of at least 1 MPa comprising incubating one or both of the surfaces in a lubricant comprising a plurality of liposomes being in their gel-phase and dispersed in an aqueous medium.
- the characteristics of the liposomes are as set forth-above.
- the method can decrease the coefficient of sliding friction to below about 5 ⁇ 10 ⁇ 3 , and even to below about 5 ⁇ 10 ⁇ 4 .
- this can be achieved and maintained even at high pressures, preferably of at least 3 Mpa, and even at a pressure which is at least 10 MPa.
- the liposome used is as described in detail hereinabove.
- the incubation is preferably conducted for at least 0.5 hours, for example from 1.5 to 2 hours.
- the surfaces can be left under incubation for prolonged periods of time (for example several days) without adversely effecting the adsorption of the liposomes to the surfaces.
- the gel-phase liposomes can also be used for the treatment of joint dysfunction in a mammalian subject by means of the lubrication of surface(s) within the joint capsule, wherein the temperature of said surfaces at the time of lubrication is below the phase transition temperature T m of said liposomes.
- the gel-phase liposomes may be used to treat, alleviate, retard, prevent, manage or cure any articular disorder or symptoms arising there from which is associated with joint dysfunction.
- articular disorder shall be held to mean any affliction (congenital, autoimmune or otherwise), injury or disease of the articular region which causes degeneration, pain, reduction in mobility, inflammation or physiological disruption and dysfunction of joints.
- the disorder may be associated with reduced joint secretion and lubrication as well as from complications of knee and hip replacement.
- the joint in accordance with the invention may be any one of the knee, hip, ankle, shoulder, elbow, tarsal, carpal, interphalangeal and intervertebral.
- Specific articular disorders include, but are not limited to, deficiencies of joint secretion and/or lubrication arising from arthritis, including conditions of joint erosion in rheumatoid arthritis, osteoarthritis, osteoarthritis in rheumatoid arthritis patients, traumatic joint injury (including sports injury), locked joint (such as in temporomandibular joint (TMJ)), status post arthrocentesis, arthroscopic surgery, open joint surgery, joint (e.g. knee or hip) replacement in mammals, preferably humans.
- a specific disorder to be treated or prevented by the method of the invention is osteoarthritis.
- the method of the present invention could be used as a prophylactic measure to prevent future damage or degeneration.
- the gel-phase liposomes could be administered intra-articularly to athletes intermittently throughout their career to minimize the risk of stress related injury or cartilage degeneration.
- the method of the present invention may be used exclusive of, or as an adjunct to, anti-inflammatory agents, analgesic agents, muscle relaxants, anti depressants, or agents that promote joint lubrication commonly used to treat disorders associated with joint stiffness, such as arthritis.
- a combined therapeutic approach is beneficial in reducing side effects associated with agents, such as non-steroidal, anti-inflammatory drugs (NSAIDs), commonly used to prevent, manage, or treat disorders such as osteoarthritis associated with reduced joint lubrication.
- NSAIDs non-steroidal, anti-inflammatory drugs
- a combined therapeutic approach may also be advantageous in increasing efficacy of treatment.
- the administration of the liposomes into an articular cavity of a patient may be by a method chosen from the group consisting of intra-articular injection, arthroscopic administration or surgical administration.
- the liposomes are administered to the mammalian subject using a physiologically acceptable carrier, such as histidine buffer (HB).
- a physiologically acceptable carrier such as histidine buffer (HB).
- composition according to the invention is preferably in a form suitable for administration by a route selected from intra-articular injection, arthroscopic administration or surgical administration.
- the amount of liposomes to be administered will vary depending on the liposome's composition, the disease, its severity and treatment regimen, as well as on the age, weight, etc., of the mammal to be treated. The amount for purposes herein is determined by such considerations as may be known in the art.
- the amount must be effective to achieve an improvement in the lubrication of the treated joint, namely, to reduce friction between the cartilages forming the joint, the improvement may be exhibited by clinical tests as well as by an improvement in the well-being of the subject undergoing said treatment (e.g. reduced pain in the afflicted joint, improvement in mobility).
- the effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount.
- the concentration of the liposomes in the aqueous carrier may be between 30 and 150 mM.
- Table 1 summarizes the lubricant compositions prepared according to preferred embodiments of the invention, and adsorbed on one or two molecularly smooth mica surfaces, as well as the lubrication properties of the obtained systems:
- System S 1 composed of two mica surfaces coated by small unilamellar vesicles (SUVs) of hydrogenated soy phosphatidylcholine (HSPC) liposomes in pure water. This system showed excellent levels of lubrication, having a friction coefficient ⁇ 10 ⁇ 4 -2 ⁇ 10 ⁇ 5 up to pressures of 12 MPa (120 atmospheres) or more;
- System S 2 composed of a bare mica and a mica coated with SUV HSPC liposomes in pure water. This system showed, for regular high surface coverage, very good levels of lubrication, ⁇ 10 ⁇ 4 , up to pressures of ca. 6 Mpa.
- System S 3 composed of SUV HSPC liposomes in physiological salt concentration of 150 mM NaNO 3 . This system showed good level of lubrication between two coated mica surfaces, ⁇ 2*10 ⁇ 4 -10 ⁇ 2 at pressures up to 6 MPa.
- System S 4 composed of positively charged SUV HSPC/DMTAP liposomes in water. This system showed very good lubrication between two coated mica surfaces, ⁇ 10 ⁇ 4 , up to pressures of ⁇ 3 MPa; for one coated surface vs.
- System S 5 composed of positively charged SUV HSPC/DMTAP liposomes in physiological salt concentration of 150 mM NaNO 3 ; This system showed very good levels of lubrication between two coated surfaces, with ⁇ 2*10 ⁇ 4 -3 ⁇ 10 ⁇ 3 up to pressures of ⁇ 6 Mpa, f) System S 6 , composed of multilamellar vesicles (MLVs) of HSPC liposomes.
- MLVs multilamellar vesicles
- System S 10 composed of two surfaces coated by SUVs of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) liposome in pure water.
- DSPC 1,2-distearoyl-sn-glycero-3-phosphocholine
- This system showed excellent levels of lubrication, having a friction coefficient ⁇ 1.5 ⁇ 10 ⁇ 4 -7 ⁇ 10 ⁇ 5 up to pressures of 11 Mpa (110 atmospheres) or more; and h) System S 11 composed of two surfaces coated by SUVs of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposome in pure water.
- DPPC 1,2-dipalmitoyl-sn-glycero-3-phosphocholine
- This system showed diverse values of effective friction coefficient ⁇ and maximal applied pressure (before friction coefficient is increased). At the optimal contact points, the system showed excellent levels of lubrication, having a friction coefficient ⁇ 2 ⁇ 10 ⁇ 4 up to pressures of 12 MPa (120 atmospheres) or more. However, due to the range of results over different contact positions and a tendency of the friction coefficient to increase at second and more entries to contact point, the overall lubrication efficiency of this system is estimated as good, level 3 (Table 1) (rather than excellent, level 5).
- Table 2 shows some comparative lubricant compositions adsorbed on one or two molecularly smooth mica surfaces, and the lubrication properties of the obtained systems:
- System C 7 composed of SUV PEGylated-HSPC liposomes in water
- System C 8 composed of SUV of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes in water
- POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
- Liposomes lubrication efficiency was scored by the inventors according to the shear reduction measured in the experimental system—the surface force balance. Value of 5 was given to the best lubrication capability as 1 to the worst.
- the MLVs were downsized to form SUVs at a HSPC concentration of 30 mM, by stepwise extrusion through polycarbonate membranes from 400-nm to 50.-nm-pore-sizes at 65° C., using a Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada.
- Water used (also for the SFB experiments) was purified (Milli-Q®Gradient A10 or Barnsted NanoPure systems) to 18.2 M ⁇ cm resistance with total organic content levels of 3-4 ppb (Milli-Q) or ⁇ ca.1 ppb (Barnstead).
- the pH of the water was 5.8 due to ions leached from glassware and dissolved atmospheric CO 2 .
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 65 ⁇ 3 nm in diameter.
- Freshly cleaved, atomically smooth mica surfaces were incubated for 1.5-2 hours at 23 ⁇ 2° C., in a dispersion consisting of 360 ⁇ 10 ⁇ L of the HSPC-SUVs prepared as described in Example S1 in 10 ml water, whereon spontaneous adsorption of the liposomes took place. The Surfaces were then washed. (1 minutes gentle waving in excess of pure water or 5 minutes standing in pure water) to remove excess, non-adsorbed liposomes and rapidly mounted in the SFB (or taken for cryo-SEM) ensuring they remained wetted throughout.
- AFM (NT-MDT, Integra) topography images were taken in water in tapping mode using silicon nitride tips of 3 ⁇ m height, spring-Constant 0.5 N/m (Olympus, OMCL-TR800PSA).
- Cryo-SEM samples of HSPC-SUV-coated mica, prepared as described above, were frozen by plunging into liquid ethane and transferred to a BAF 60 freeze fracture device (Bal-Tec AG, Liechtenstein). Water was sublimed at ⁇ 80° C. for 2 hrs. Samples were rotary-shadowed with 3 nm Pt at an angle of 45°. Samples were transferred to an Ultra 55 SEM (Zeiss, Germany) using a VCT 100 vacuum-cryo transfer system (Bal-Tec AG, Liechtenstein) and observed at voltages of 2.5-5 kV.
- HSPC-liposome coated Mica Freshly cleaved mica surfaces were incubated in a dispersion of HSPC-SUV with a unimodal size distribution (diameter 65 nm), prepared as described herein, then rinsed and mounted in a surface force balance (SFB) filled with pure water. Similar liposome-coated mica surfaces were imaged using atomic force microscopy (AFM) and cryo-scanning-electron-microscopy (cryo-SEM), as shown in FIG. 1 .
- AFM atomic force microscopy
- cryo-SEM cryo-scanning-electron-microscopy
- the cryo-SEM image shows a honeycomb pattern characteristic of flattened close-packed spheres, overlaid by a loose, sparse layer of individual liposomes, which were not fully removed by the rinsing following the incubation.
- the AFM image shows that the liposomes are flattened by the adsorption from their unperturbed dispersion diameter to ca. 20 nm.
- This system showed, for high surface coverage, very good levels of lubrication, ⁇ 10 ⁇ 4 , up to pressures of ca. 6 Mpa, and for the low surface coverage (namely after extensive washings) showed high friction at pressures higher than 1 MPa.
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 75 ⁇ 3 nm in diameter. Coating of Solid Mica Surfaces with Liposomes Prepared by Example S3:
- HSPC-SUV were adsorbed on atomically smooth mica surface by placing freshly cleaved mica in 10 ml 150 mM NaNO 3 and then adding 360 ⁇ 10 ⁇ L of the liposome dispersion (of concentration of 30 mM) for 1.5-2 hours of incubation. Then mica surfaces were washed to remove excess, non-adsorbed liposomes by placing the adsorbed surfaces in a beaker filled with 150 mM NaNO 3 for a few minutes along with a delicate shake motion. All preparations were done in a laminar hood to prevent contamination.
- MLV were downsized to form small unilamellar vesicles (SUV), 65 nm in diameter, at a concentration of 15 mM, by stepwise extrusion through polycarbonate membranes starting with a 400-nm and ending with 50-nm-pore-size membrane, using a Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada).
- SUV small unilamellar vesicles
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 75 ⁇ 3 nm in diameter.
- Shear measurements of 2 HSPC/DMTAP coated mica surfaces in pure water show no response to shear up to pressures of 25 ⁇ 6 atm.
- a shear trace test demonstrated the low Fs as P ⁇ ⁇ 30 atm.
- Shear measurements of 1 HSPC/DMTAP coated surface vs. bare mica in pure water showed rigid coupling already in pressures of ⁇ 10 atm.
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 61.9 nm in diameter.
- the zeta potential of liposomes was 4.18 mV after replacing the external medium with 150 mM NaNO 3 .
- HSPC/DMTAP SUV were adsorbed on atomically smooth mica surface by placing freshly cleaved mica in 10 ml 150 mM NaNO 3 salt solution and then adding 720 ⁇ 20 ⁇ L of the liposome dispersion for 1 hour of incubation. After 1 hour the mica surfaces were placed in 400 ml beaker of 150 mM NaNO 3 for 1-2 minutes in order to remove excess, non-adsorbed liposomes.
- Cryo-SEM samples (mica surfaces covered with HSPC:DMTAP 95:5 liposomes) were prepared as described above, with additional rinsing step by placing the sample in pure water for few seconds in order to remove salt. Samples were frozen by plunging into liquid ethane and transferred to a BAF 60 freeze fracture device (BAl-Tec AG, Liechtenstein). Water was sublimed in the BAF 60 at a temperature of ⁇ 100 degrees for 1 hour. Pt cover of the samples by rotary shadowing of 1.5 nm followed by 1.5 nm of Pt in an angle of 45 degrees.
- the resistance of water was 18.2 MO cm with total organic compound (TOC) ⁇ ca.1 ppb (Barnstead).
- MLV HSPC mean radius size of 1.24 ⁇ 0.57 ⁇ m was measured with particle size analyzer LS 13 320 equipped with the PIDS unit which can determine particle size at the range of 40 nm to 2.0 mm (Beckman Coulter).
- Shear force measurements between a mica surface covered with HSPC MLVs liposomes in opposing to a bare mica surface in pure water at different surface separation D and applied normal force (pressure) show that a similar shear force was measured during the first approach to a contact point and on during the second approach.
- the MLVs were downsized to form SUVs at a final concentration of 15 mM, by stepwise extrusion through polycarbonate membranes from 400-nm to 50-nm-pore-sizes at 65° C., using a Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada.
- FIG. 2 The shear traces and resulting load vs. friction data are shown in FIGS. 5A and 5B , revealing excellent lubrication up to high pressures (>100 atms). Cryo-SEM micrographs of the DSPC-SUV on mica revealed close-packed layers on the surface.
- the MLVs were downsized to form SUVs at a final concentration of 15 mM, by stepwise extrusion through polycarbonate membranes from 400-nm to 50-nm-pore-sizes at around 60° C., using a Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada.
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Size (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 65 ⁇ 10 nm in diameter.
- SUV HSPC/PEG liposome mixtures in water were prepared as a comparative example, since the PEG external head groups have an end-to-end radius which is larger than 1 nm (being 4 nm).
- the HSPC/PEG liposomes were prepared and characterized as described in Langmuir 21, 2560 (2005).
- SUV POPC liposomes in water were prepared as a comparative example, since the obtained liposome has a Tm which is smaller than the measuring temperature, being smaller than about 15° C. (being ⁇ 3° C.).
- 0.456 gr POPC were dissolved in hot ethanol to a concentration of 0.45 w/v. This solution was injected into pure water at temperature of 250° C.
- MLV multilamellar liposomes
- Liposomes were characterized for size distribution by dynamic light scattering using Malvern Zetasizer—nano series (Malvern Instrument Limited—UK) at a scattering angle of 173°. 100% of the liposomes were 68.8 nm in diameter.
- Table 1 describes the lipids (>98% pure) used in this experiment.
- Multilamellar vesicles composed of pure Phosphatidylcholines (PCs): POPC, DMPC and HSPC, were prepared by hydrating the lipids in at least 5° C. above the lipid T M .
- MLVs were downsized by stepwise extrusion through polycarbonate membranes starting with a 400-nm and ending with 50-nm-pore-size membrane, using a Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada), heated at least 5° C. above the lipid T M .
- MLVs liposomes concentration was of 130 ⁇ 10 mM
- SUVs liposomes concentration was of 35 ⁇ 5 mM.
- Friction testing was carried out using a CETR ⁇ tribometer, UMT model with high sensor which enables high normal loads.
- the system configuration was of a cartilage on a cartilage setup, in which two samples of bovine cartilage are immersed in HB, saline (0.9% w/v) or in synovial fluid (SF, obtained from the fresh bovine joints).
- the cartilage samples were subjected to relative sliding over a wide range of loads of 1 to 12 kg (10 to 120 N), equivalent to physiological pressures in joints (0.73 ⁇ 0.1 MPa to 8.75 ⁇ 1.25 MPa).
- the testing parameters were the following: Sliding velocity of 1 mm/sec, sliding amplitude of 1.5 mm and dwell time of 5 sec. Experiments were at room temperature (ca. 25 ⁇ 1 C)
- the static friction coefficient is obtained from the maximum value from the shear trace, and the kinetic friction coefficient is calculated as the average value at the sliding region.
- the data summaries are based on the mean of 2-3 independent experiments (i.e. 2-3 fresh pairs of cartilage surfaces) in each case, except for the synovial fluid control (1 experiment), and 40 back-and-forth cycles per measurement. The cartilage surfaces were incubated for 30 mins in the liposome solutions prior to friction measurements.
- Phase transition temperature Short name Chemical name MW (T m ), ° C. POPC 1-palmitoyl-2-oleoyl- 760.1 ⁇ 3 sn-glycero-3- phosphocholine DMPC 1,2-dimyristoyl-sn- 677.9 23.2 glycero-3- phosphocholine HSPC hydrogenated soybean 762.1 52.5 phosphocholine
- FIG. 1 Cryo-SEM image of the HSPC-SUV adsorbed on freshly cleaved mica as described in Methods section;
- the inset compares profiles on a first approach (full symbols) and second approach (corresponding empty symbols) from different contact positions.
- FIG. 3 Typical shear (or friction) force Fs vs. time traces between HSPC-SUV coated mica surfaces taken directly from SFB;
- FIG. 4 4 A: Friction forces Fs vs. applied loads Fn between two HSPC-SUV-coated mica surfaces, based on traces such as in FIG. 3. 4B : Friction forces F s variation with sliding velocity for different compressions ( ⁇ 74 atm; 94 atm; ⁇ 107 atm; 118 atm) of HSPC-SUV coated mica surfaces showing little variation within the scatter over nearly 3 decades in v s .
- FIG. 5A Shear traces between two mica surfaces coated with SUV-DSPC liposomes in pure water, measured using the surface force balance showing the shear force Fs vs. time. The traces demonstrate the shear force at different surface separations under various applied pressures.
- FIG. 5B Friction force vs. the applied normal load between two SUV-DSPC coated mica surfaces, based on traces such as in 5 A.
- FIG. 6 Dynamic ( 6 A) and Static ( 6 B) Friction coefficients vs. load (N) according to preferred embodiments of the invention for bovine articular cartilage surfaces following incubation in HSPC-MLV, DMPC-MLV, and POPC-MLV liposome solutions in histidine buffer.
- FIG. 7 Dynamic and Static friction coefficients for different systems (both controls and with liposomes) for a 30N load ( FIG. 7A ) and for a 120N load ( FIG. 7B ) between sliding bovine cartilage surfaces according to preferred embodiments of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmacology & Pharmacy (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
- Liposomes are vesicles whose membranes in most cases are based on phospholipid bilayers. They are generally biocompatible and, when modified with other molecules, are widely used in clinical applications, primarily as drug delivery vehicles, as well as in gene therapy and for diagnostic imaging.
- WO 08/038,292, by some of the present inventors, disclosed, inter alia, multilamellar vesicles (MLVs) of several phospholipids above their liquid-crystalline-phase to gel-phase transition temperature Tm as possible boundary lubricants in the articular cartilage environment.
- Presently, there is a serious lack of good solutions to the problem of boundary lubrication in aqueous media. Boundary lubrication in aqueous media is often problematic as water on its own is not a good lubricant, while common surfaces or surface coatings in water frequently exhibit quite high friction (with friction coefficients μ>0.01-0.05), especially at high pressures.
- The problem is even more evident when extremely low friction is required, particularly at high pressures (up to 100 atmospheres or more) and at low sliding velocities. For example, Values of ca. 2×10−3 or lower have been measured between some physically-attached boundary lubricants, but these were at mean contact pressures of only up to 0.3 MPa (3 atmospheres) or less. In Chen, M., Briscoe, W. H., Armes, S. P., and Klein, J [Lubrication at Physiological Pressures by Polyzwitterionic Brushes, Science 323, 1698 (2009)] it is reported that boundary lubricants which were covalently grown on surfaces demonstrate low friction coefficients, around 10−3, up to 75 atmospheres pressure.
- Vecchio, P.; Thomas, R.; Hills [B. A. Rheumatology 1999, 38(10), 1020-1021] describe the injection of dipalmitoylphosphatidylcholine (DPPC) solutions in propylene glycol into joints.
- U.S. Pat. No. 6,800,298 describes a lubricant composition comprising dextran-based hydrogel with lipids.
- There is a need for an alternative physically-attached boundary lubricant in aqueous media, which would have a low friction coefficient even at contact pressures substantially higher than 0.3 MPa.
- It has now been surprisingly found that it is possible to use gel-phase liposomes as lubricants. Liposomes are known to transform from their gel (solid) phase to liquid crystalline phase at a characteristic temperature designated Tm, defined as the temperature at which the maximal change in the excess heat capacity (kcal/mol/deg) occurs. The lubrication properties of gel phase liposomes, namely, liposomes applied onto surfaces at a temperature which is lower than their Tm, were tested and were found to be particularly good. It has been found that gel-phase liposomes are especially useful for lubricating surfaces that are subject to high pressure, up to 120 atmospheres (around 120 MPa) or more. Notably, when the pressure exerted over the surface is above 30 atmospheres (3 MPa), then the lubrication provided by the gel-phase liposomes, is better than that of liquid-phase liposomes. Thus, the gel-phase liposomes may be used according to the invention for the treatment of joint dysfunction, wherein the pressure within the joint reaches values in the range of 30 to 120 atmospheres (3-12 MPa). Characteristic pressures in joints are reported in the following references:
- 1. Afoke, N. Y. P., Byers, P. D., and Hutton, W. C., Contact pressures in the human hip joint. J. Bone Joint Surgery 69B, 536 (1987).
- 2. Hodge, W. A., Fuan, R. S., Carlson, K. L., Burgess, R. G., Harris, W. H., and Mann, R. W., Contact pressures in the human hip joint measured in vivo. Proc. Natl. Acad. Sci. USA 83, 2879 (1986).
- As demonstrated in the experimental section below, gel-phase liposomes of different compositions and size characteristics can provide efficient lubrication in aqueous environments on solid surfaces on which they spontaneously adsorb to form surface coatings. The lubrication (yielding, in most cases, values μ<ca. 1×10−3) occurs under pressures of up to 120 atmospheres or more, and down to very low sliding velocities, with little apparent wear of the liposome surface coatings.
- Thus, in a first aspect, the invention provides a method for lubricating one or more non-biological surfaces (in particular negatively charged solid surfaces), comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes.
- The invention also provides a method for lubricating one or more surfaces of a biological tissue in a mammalian subject (for example, a cartilage surface within a joint capsule), comprising applying gel-phase liposomes onto said one or more surfaces, wherein the temperature of said surface(s) at the time of lubrication is below the phase transition temperature Tm of said liposomes. The use of gel-phase liposomes for lubricating surfaces having a surface temperature which is below the phase transition temperature Tm of said liposomes, constitutes another aspect of the invention. The invention also encompasses a therapeutic composition for lubricating the surface of a biological tissue in a mammalian subject, wherein said composition comprises gel-phase liposomes and an aqueous carrier.
- More specifically, the invention provides the use of gel-phase liposomes in the preparation of a therapeutic composition for the treatment of joint dysfunction in a mammalian subject by means of the lubrication of cartilage surface(s) within the joint capsule, wherein the temperature of said surfaces at the time of lubrication is below the phase transition temperature Tm of said liposomes. The invention also provides gel-phase liposomes for the treatment of joint dysfunction in a mammalian subject by means of the lubrication of surface(s) within the joint capsule, wherein the temperature of said surfaces at the time of lubrication is below the phase transition temperature Tm of said liposomes. The maximal pressure within the joint is in the range of 30 to 120 atmospheres (3-12 MPa). The carrier used for administering the liposomes to the mammalian subject is preferably an aqueous carrier (e.g., an aqueous-based buffer solution) free of organic co-solvents or extraneous organic compounds (other than of course the liposomes).
- Gel-phase Liposomes to be used according to the invention are based on phosphocholine-containing lipids and mixtures thereof. However, it is possible to combine lipids having polar head groups other than phosphocholine in the gel-phase liposomes. Liposomes operable in the invention have external (exposed at the outer liposome surface) polar head groups which are composed of at least 95 mole % phosphocholine groups, and of up to 5 mole % external non-phosphocholine head group having an unperturbed-end-to-end radius in aqueous medium equal to or smaller than about 1 nm, or cross-section parameter which is less than 0.8 nm2, (provided, of course that said liposomes are in their gel-phase and have a Tm which is higher than the intended working temperature).
- In contrast, liposomes in which the up to 5 mole % external non-phosphocholine head group units have an unperturbed-end-to-end radius (in the aqueous medium) which is larger than about 1 nm, are not suitable for use as lubricant compositions since the systems formed by incubating the solid surfaces therein have a high friction coefficient. For example, liposomes in which the 5% of external non-phosphocholine head groups were the PEG groups of DSPE-PEG2000, having an unperturbed-end-to-end radius (in aqueous medium) of about 4 nm, demonstrated poor lubrication properties, having friction coefficients of 0.05 to 0.1 (Example C7, see below).
- As noted above, the presence of head groups other than phosphocholine units in the gel-phase liposomes is permitted, provided that the unperturbed-end-to-end radius of said non-phosphocholine groups is less than 1 nm, or their cross section is less than 0.8 nm2.
- The term “unperturbed-end-to-end radius” means the steric size of said head group when it is not subject to external constraints, and is used herein in order to estimate the radius of non-phosphocholine head groups which are polymer chains (such as PEG chain in the case of DSPE-PEG2000 lipid) and also for non-phosphocholine head groups which are molecular/cationic entities (such as the TAP group in the 1,2-dimyristoyl-3-trimethylammonium-propane (DMATP)).
- By way of the example, the size of the charged head-group on the DMTAP is approximately 0.3-0.5 nm and its radius would be about half of that, say 0.2 nm. Thus, lipids which contain the TAP head group (and two hydrocarbon saturated chains) can be combined with phosphocholine-containing lipids to form liposomes which are suitable for use in the invention.
- An alternative way for estimating the size of the polar head group of the lipid is by means of its cross section parameter, as described by Lewis, R. N. A. H., S. Tristram-Nagle, J. F. Nagle, and R. N. McElhaney [The thermodynamic phase behavior of cationic lipids: calorimetric, infrared spectroscopic and X-ray diffraction studies of lipid bilayer membranes composed of 1,2-di-O-myristoyl-3-N,N,N-trimethylaminopropane (DM-TAP). Biochim. Biophys. Acta. 1510:70-82, 2001].
- In the case of non-phosphocholine head groups which are polymer chains with N backbone units, characteristic ratio C∞, and mean backbone unit size x, the unperturbed-end-to-end radius R0 is given by:
-
R 0=(NC ∞)1/2 x - For the particular case of polyethylene glycol (PEG) of
molecular weight 2000, say, the number of backbone units is N=2000/(44/3), C∞=4.9±0.1, and x≈0.15 nm, so that the unperturbed-end-to-end radius in this case is R0=ca. 3.9 nm. - Preferably, the gel-phase liposomes used according to the invention comprise one or more phosphatidylcholine lipids, with the Tm values of the liposomes being not less than 40° C., preferably not less than 45° C. Mixtures of different phosphatidylcholine lipids can be used to form the liposomes, with the molar ratio between the components of the mixture being adjusted to produce liposomes having the desired Tm value [see Scott et al., Biophysical Journal (28), p. 117-132 (1979)]. According to one embodiment of the invention, Tm is not less than 50° C., e.g., from 50 to 60° C. According to one embodiment, the hydrocarbon tails of the phosphatidylcholine lipids are saturated and contain not less than 17 carbon atoms. In particular, it has now been found that liposomes comprising hydrogenated soy phosphatidylcholine (HSPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and dipalmitoylphosphatidylcholine (DPPC) and mixtures thereof may act as efficient lubricants in aqueous media even at physiologically high pressures of up to 120 atmospheres (85% of the HSPC are DSPC and 15% are the sum of 1 stearoyl 2-palmitoyl PC plus 1-palmitoyl 2-steroyl PC). The Tm values for HSPC, DSPC and DPPC are 52.5° C., 55° C. and 41.4° C., respectively. Tm values of various PC-based lipids may be found in “Thermotropic Phase Transitions of Pure Lipids in Model Membranes and Their Modifications by Membrane Proteins”, John R. Silvius, Lipid-Protein Interactions, John Wiley & Sons, Inc., New York, 1982, and also in the Lipid Thermotropic Phase Transition Data Base—LIPIDA.
- According to another preferred embodiment of the invention, the liposomes to be used are in the form of small unilamellar vesicles (SUV). For example, it has been shown that small unilamellar vesicles (SUVs) of hydrogenated soy phosphatidylcholine (HSPC) lipids self-assembled in close-packed layers on solid surfaces, thereby reducing the coefficient μ of sliding friction between these surfaces down to values μ≈10−4-2×10−5, at pressures of up to ca. 12 MPa (ca. 120 atmospheres) and possibly higher. Such low values of the friction have so far been attained in other physically-attached boundary lubricants only at mean contact pressures of up to 0.3 MPa or less, these being lower by up to 40-fold or more than the pressures reached with the presently disclosed liposome composition (12 MPa). According to another preferred embodiment, the SUV liposomes have a mean diameter which is smaller than 100 nm. Good to excellent lubrication between solid surfaces coated by SUVs of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and by SUVs of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), has also been achieved at comparably high pressures as seen in Table 1 and described below.
- Thus, according to a preferred embodiment, at least 95% of the external polar head groups of the gel-phase liposomes used in the method of the invention are phosphoryl choline head group, the liposomes being in the SUV form and having a mean diameter which is smaller than 100 nm. Preferably, these gel-phase SUV PC-based liposomes have a mean diameter ranging from about 60 nm to about 80 nm, more preferably ranging from about 65 nm to about 75 nm.
- Furthermore, it has been shown that multilamellar vesicles (MLVs) of hydrogenated soy phosphatidylcholine (HSPC) lipids self-assembled on solid surfaces, and effectively reduced the coefficient μ of sliding friction between these surfaces down to values in the range of μ=7×10−3 to 5×10−4, for both first and second approaches as pressures are up to 3 Mpa (˜30 atm).
- Thus, according to yet another preferred embodiment of the invention, the liposomes in the compositions described herein, are in the form of multilamellar vesicles (MLVs). Preferably, these liposomes have a mean diameter larger than 200 nm, yet more preferably larger than 500 nm, and most preferably of about 1 micron and larger.
- Preferred liposomes to be used according to the invention, for example for lubricating non-biological surfaces, consist of HSPC, DSPC or DPPC lipids. These PC-based liposomes exhibit good to excellent lubrication results under various conditions, as can be seen in Examples S1, S2, S3, S6, S10 and S11.
- Another class of preferred liposomes to be used according to the invention, for example for lubricating non-biological surfaces, is based on a mixture comprising a first lipid, which is phosphocholine-containing lipid (e.g., HSPC, DSPC or DPPC, or their mixtures) and a second lipid, which contains TAP hydrophilic head group, wherein the mole ratio between said first and second lipids is from 95:5 to 99.9:0.1. The second lipid, namely, the TAP-containing lipid has two hydrocarbon chains which independently contain 14, 16 or 18 carbon atoms. Preferably, the TAP-containing liposome is selected from the group consisting of 1,2-ditetradecanoyl-3-trimethylammonium-propane (DMTAP), 1,2-dipalmitoyl-3-dimethylammonium-propane and 1,2-disteraroyl-3-dimethylammonium-propane, which are also described as 14:0 TAP, 16:0 TAP and 18:0 TAP, respectively, indicating that the length of both chains of the lipid is the same (being 14, 16 and 18, respectively). The “mixed” liposome exhibits very good lubrication results under various conditions, as can be seen in Examples S4 and S5. The mixed liposomes having the composition set for the above are believed to be novel and form a further aspect of the present invention.
- It should be noted that the good lubrication results were obtained for different aqueous mediums, for example in pure water, as well as in physiological salt solution.
- Furthermore, the good lubrication was obtained also when the surface of the liposomes was positively charged (for example, when some of the zwiterionic HSPC molecules were replaced by charged DMTAP cationic lipids).
- It has been found that liposomes having positively charged surface showed improved lubrication with the negatively-charged solid surfaces in water at high salt concentrations (for example, not less than 0.05M of a 1:1 salt, e.g., not less than 0.15M), as compared to liposomes having positively charged surface used in water containing no added salt.
- Thus, according to preferred embodiments of the invention, the gel-phase liposomes to be used have positively charged surfaces. As shown hereinbelow, the liposomes used according to the present invention adsorb spontaneously onto negatively charged solid surfaces in water, to form close-packed boundary layers that provided uniquely efficient lubrication, resulting in friction coefficients down to 2×10−5 at pressures of more than 100 atmospheres (above 10 MPa). This extremely low friction at such high pressures makes these liposomes extremely suitable for providing efficient lubrication in aqueous media. It should be understood, however, that the surfaces to be treated by the liposomes in accordance with the invention may be overall neutral, but having discrete positive and negative regions, such that the liposomes attach to the negatively-charged regions, or even to overall-positively charged surfaces if there are also negatively charged patches on them onto which the liposomes may attach. Positively-charged surfaces can also be treated with gel-phase phosphatidylcholine liposomes with up to 5 mole % of negatively-charged lipids such as phosphatidic acid (PA), phopsphatidyl glycerol (PG), phopsphatidyl inositil (PI) and phosphatidylserine (PS).
- Thus, according to another aspect of the invention, there is provided a lubricant system comprising a plurality of liposomes being in their gel-phase and further being spontaneously adsorbed on at least one of two negatively charged solid surfaces, in an aqueous medium. The characteristics of the liposomes are as set forth above.
- Suitable negatively charged solid surfaces include, but are not limited to, glass, mica and cartilage.
- For example, the gel-phase liposomes to be used according to the invention proved as efficient lubricants when coated on one or two mica surfaces, having friction coefficients lower than 1×10−2 and even lower than 5×10−3 and 15×10−4.
- Thus, according to preferred embodiments of the invention, the lubricant system described herein has a coefficient of sliding friction between the above-described surfaces which is less than about 1×10−2 under a pressure of at least 1 Mpa, in the aqueous medium.
- The improved friction results were obtained even at high pressures (much higher than 0.3 MPa as known in the art for physically-attached boundary lubricants), namely pressures which were at least 1 Mpa, 3 Mpa, 6 Mpa and 10 Mpa, even reaching 12 MPA. It is believed that the improved friction shall be exhibited even at higher pressures.
- Furthermore, the good lubrication under pressure is now maintained repeatedly, for a large number of additional back-and-forth sliding cycles. This phenomenon is important since under physiological solutions, normal application of lubricants may involve very large numbers of repetitive cycles. According to the present invention, not only does the lubricant remain attached or adsorbed to the surface upon application of pressure, but it may remain so even after additional similar pressure cycles.
- These findings demonstrate that the liposomes described herein may reduce friction between surfaces onto which they spontaneously adsorb, up to the maximal pressures pertaining in mammalian joints, to levels that are even lower than between healthy sliding articular cartilage. Such low friction between surfaces in aqueous media at these high pressures has not hitherto been attained by any physically-attached boundary lubricant system.
- Thus, according to another aspect of the invention, there is further provided a method of decreasing the friction coefficient between two negatively charged solid surfaces in aqueous medium to below about 1×10−2 under a pressure of at least 1 MPa, the method comprising incubating one or both of the surfaces in a lubricant comprising a plurality of liposomes being in their gel-phase and dispersed in an aqueous medium. The characteristics of the liposomes are as set forth-above.
- According to preferred embodiments of the invention, the method can decrease the coefficient of sliding friction to below about 5×10−3, and even to below about 5×10−4.
- Most advantageously, this can be achieved and maintained even at high pressures, preferably of at least 3 Mpa, and even at a pressure which is at least 10 MPa.
- In order to effectively reduce the friction coefficient as described herein, the liposome used is as described in detail hereinabove. Furthermore, the incubation is preferably conducted for at least 0.5 hours, for example from 1.5 to 2 hours. However, it should be noted that the surfaces can be left under incubation for prolonged periods of time (for example several days) without adversely effecting the adsorption of the liposomes to the surfaces.
- The incubation as described in the examples was conducted at about room temperature, but this can vary according to the desired application.
- As already noted above, the gel-phase liposomes can also be used for the treatment of joint dysfunction in a mammalian subject by means of the lubrication of surface(s) within the joint capsule, wherein the temperature of said surfaces at the time of lubrication is below the phase transition temperature Tm of said liposomes. The gel-phase liposomes may be used to treat, alleviate, retard, prevent, manage or cure any articular disorder or symptoms arising there from which is associated with joint dysfunction. For the purposes of this disclosure the term “articular disorder” shall be held to mean any affliction (congenital, autoimmune or otherwise), injury or disease of the articular region which causes degeneration, pain, reduction in mobility, inflammation or physiological disruption and dysfunction of joints. The disorder may be associated with reduced joint secretion and lubrication as well as from complications of knee and hip replacement.
- The joint in accordance with the invention may be any one of the knee, hip, ankle, shoulder, elbow, tarsal, carpal, interphalangeal and intervertebral.
- Specific articular disorders include, but are not limited to, deficiencies of joint secretion and/or lubrication arising from arthritis, including conditions of joint erosion in rheumatoid arthritis, osteoarthritis, osteoarthritis in rheumatoid arthritis patients, traumatic joint injury (including sports injury), locked joint (such as in temporomandibular joint (TMJ)), status post arthrocentesis, arthroscopic surgery, open joint surgery, joint (e.g. knee or hip) replacement in mammals, preferably humans. A specific disorder to be treated or prevented by the method of the invention is osteoarthritis.
- The method of the present invention could be used as a prophylactic measure to prevent future damage or degeneration. For example, the gel-phase liposomes could be administered intra-articularly to athletes intermittently throughout their career to minimize the risk of stress related injury or cartilage degeneration.
- The method of the present invention may be used exclusive of, or as an adjunct to, anti-inflammatory agents, analgesic agents, muscle relaxants, anti depressants, or agents that promote joint lubrication commonly used to treat disorders associated with joint stiffness, such as arthritis. A combined therapeutic approach is beneficial in reducing side effects associated with agents, such as non-steroidal, anti-inflammatory drugs (NSAIDs), commonly used to prevent, manage, or treat disorders such as osteoarthritis associated with reduced joint lubrication. In addition to enhancing safety, a combined therapeutic approach may also be advantageous in increasing efficacy of treatment.
- The administration of the liposomes into an articular cavity of a patient may be by a method chosen from the group consisting of intra-articular injection, arthroscopic administration or surgical administration.
- In accordance with one embodiment, the liposomes are administered to the mammalian subject using a physiologically acceptable carrier, such as histidine buffer (HB).
- The composition according to the invention is preferably in a form suitable for administration by a route selected from intra-articular injection, arthroscopic administration or surgical administration.
- The amount of liposomes to be administered will vary depending on the liposome's composition, the disease, its severity and treatment regimen, as well as on the age, weight, etc., of the mammal to be treated. The amount for purposes herein is determined by such considerations as may be known in the art.
- The amount must be effective to achieve an improvement in the lubrication of the treated joint, namely, to reduce friction between the cartilages forming the joint, the improvement may be exhibited by clinical tests as well as by an improvement in the well-being of the subject undergoing said treatment (e.g. reduced pain in the afflicted joint, improvement in mobility). The effective amount is typically determined in appropriately designed clinical trials (dose range studies) and the person versed in the art will know how to properly conduct such trials in order to determine the effective amount. For example, the concentration of the liposomes in the aqueous carrier may be between 30 and 150 mM.
- Table 1 below summarizes the lubricant compositions prepared according to preferred embodiments of the invention, and adsorbed on one or two molecularly smooth mica surfaces, as well as the lubrication properties of the obtained systems:
- a) System S1, composed of two mica surfaces coated by small unilamellar vesicles (SUVs) of hydrogenated soy phosphatidylcholine (HSPC) liposomes in pure water. This system showed excellent levels of lubrication, having a friction coefficient μ≈10−4-2×10−5 up to pressures of 12 MPa (120 atmospheres) or more;
b) System S2, composed of a bare mica and a mica coated with SUV HSPC liposomes in pure water. This system showed, for regular high surface coverage, very good levels of lubrication, μ≈10−4, up to pressures of ca. 6 Mpa.
c) System S3, composed of SUV HSPC liposomes in physiological salt concentration of 150 mM NaNO3. This system showed good level of lubrication between two coated mica surfaces, μ≈2*10−4-10−2 at pressures up to 6 MPa.
d) System S4, composed of positively charged SUV HSPC/DMTAP liposomes in water. This system showed very good lubrication between two coated mica surfaces, μ≈10−4, up to pressures of ˜3 MPa; for one coated surface vs. mica, μ≈3.5*10−2, at pressures up to ˜1.3 MPa;
e) System S5, composed of positively charged SUV HSPC/DMTAP liposomes in physiological salt concentration of 150 mM NaNO3; This system showed very good levels of lubrication between two coated surfaces, with μ≈2*10−4-3×10−3 up to pressures of ˜6 Mpa,
f) System S6, composed of multilamellar vesicles (MLVs) of HSPC liposomes. This system showed good lubrication between one coated surface and a bare mica surface, μ≈5*10−4-7*10−3 at pressures up to 30 Mpa,
g) System S10, composed of two surfaces coated by SUVs of 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) liposome in pure water. This system showed excellent levels of lubrication, having a friction coefficient μ≈1.5×10−4-7×10−5 up to pressures of 11 Mpa (110 atmospheres) or more; and
h) System S11 composed of two surfaces coated by SUVs of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) liposome in pure water. This system showed diverse values of effective friction coefficient μ and maximal applied pressure (before friction coefficient is increased). At the optimal contact points, the system showed excellent levels of lubrication, having a friction coefficient μ≈2×10−4 up to pressures of 12 MPa (120 atmospheres) or more. However, due to the range of results over different contact positions and a tendency of the friction coefficient to increase at second and more entries to contact point, the overall lubrication efficiency of this system is estimated as good, level 3 (Table 1) (rather than excellent, level 5). - In addition, Table 2 below shows some comparative lubricant compositions adsorbed on one or two molecularly smooth mica surfaces, and the lubrication properties of the obtained systems:
- a) System C7, composed of SUV PEGylated-HSPC liposomes in water, is a comparative example. This system showed poor lubrication levels, with μ≈0.05-0.1 at pressures up to ca. 2.5 Mpa; and
System C8, composed of SUV of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) liposomes in water, is another comparative example; This system showed poor lubrication levels, for 2nd approach μ≈0.1 up to 3 MPa pressures. - In both tables, Liposomes lubrication efficiency was scored by the inventors according to the shear reduction measured in the experimental system—the surface force balance. Value of 5 was given to the best lubrication capability as 1 to the worst.
-
TABLE 1 Lubrication efficiency Liposome μ Short Chemical diameter Tm Surface Pmax Relative Friction name composition SUV/MLV [nm] [° C.] charge Medium [atm] efficiency coefficient S1 HSPC L-α- SUV 65 ± 3 52.5 zwiterionic pure ~120 5 excellent phosphatidylcholine, water lubrication hydrogenated (Soy) 2 × 10−5-10−4 (both surfaces coated) S2 HSPC L-α- SUV 65 ± 3 52.5 zwiterionic pure ~60 4 very good phosphatidylcholine, water lubrication hydrogenated (Soy) 10−4 (one surface only coated) S3 HSPC L-α- SUV 75 ± 3 52.5 zwiterionic 150 mM ~60 3 good phosphatidylcholine, NaNO3 lubrication hydrogenated (Soy) 2 × 10−4-10−2 S4 HSPC:DMTAP/ L-α- SUV 65 ± 3 52.5 cationic pure ~30* 4 very good 95:5 phosphatidylcholine and water lubrication mole hydrogenated (Soy): 32 10−4* ratio 1,2-dimyristoyl-3- trimethylammonium- propane (chloride salt) S5 HSPC:DMTAP/ L-α- SUV 65 ± 3 52.5 cationic 150 mM ~60 4 very good 95:5 phosphatidylcholine and NaNO3 lubrication mole hydrogenated (Soy): 32 2 × 10−4-3 × ratio 1,2-dimyristoyl-3- 10−3 trimethylammonium- propane (chloride salt) S6 HSPC L-α- MLV 1240 ± 570 52.5 zwiterionic pure ~30 3 good phosphatidylcholine, water lubrication hydrogenated (Soy) 5 × 10−4-7 × 10−3 S10 DSPC 1,2-distearoyl-sn- SUV 65 ± 10 55 zwiterionic pure ~110 5 Excellent glycero-3- water lubrication phosphocholine 1.5 × 10−4-7 × 10−5 S11 DPPC 1,2-dipalmitoyl-sn- SUV 65 ± 10 41.4 zwiterionic pure ~120# 3# good glycero-3- water lubrication#, phosphocholine 2 × 10−4 *These values are for the symmetric system, where both surfaces are coated with liposome layer(s). For the asymmetric case of coated surface against a bare mica, the values show a much less efficient lubrication. #These values represent the lowest friction coefficients (2 × 10−4), measured at the maximal pressure (~120 atm) applied in this system (DPPC-SUV on solid mica surfaces). Because this DPPC-SUV system showed a wider diversity of values relative to the other systems described, and a tendency of μ to increase at subsequent approaches to contact point, the relative efficiency is given as 3, and the friction coefficient is described as good lubrication (rather than 5 and excellent lubrication which would be suggested by the friction-coefficient/pressure values shown). -
TABLE 2 Lubrication efficiency Liposome μ Short Chemical SUV/ diameter Tm Surface Pmax Relative Friction name composition MLV [nm] [° C.] charge Medium [atm] efficiency coefficient C7 HSPC:DSPE- L-α-phosphatidylcholine SUV ~70 52.5 Slightly pure ~10 1 poor PEG2000 hydrogenated (Soy): 1,2- and negative water lubrication 95:5 distearoyl-sn-glycero-3- 75*** 0.05-0.1 mole ratio phosphoethanolamine-N- [amino(polyethylene glycol)-2000] (ammonium salt) C8 POPC 1-palmitoyl-2-oleoyl-sn- SUV 66 ± 3 −3 zwiterionic pure ~10* 1 poor glycero-3- water lubrication phosphocholine 0.1** *These values are for the symmetric system, where both surfaces are coated with liposome layer(s). For the asymmetric case of coated surface against a bare mica, the values show a much less efficient lubrication. **These values were measured upon second entries and more to the contact point. Upon first entry to contact point higher pressures of ~30 atm were measured, related to lower values of μ of 3 × 10−3. These changes were related to damaging and squeezing the soft liposome layers attached on the surface. ***This value applies for DSPE with no attached PEG. - Surface Force Balance (SFB):
- The SFB and its protocols for measuring normal and shear forces have been described in detail by Klein, J. and Kumacheva, E., Simple liquids confined to molecularly thin layers. I. Confinement-induced liquid to solid phase transitions. J. Chem. Phys. 108 (16), 6996 (1998). Experimental runs were carried out by compressing the surfaces to progressively higher pressures, then decompressing by separating them, following which shear forces were measured on second and (in several cases) subsequent compressions at the same contact point, before moving to a different contact point. The results in each case were based on several independent experiments (different pairs of mica surfaces, different. PC-SUV batches), each with multiple contact points. All measurements were carried out at 23.5±0.5° C.
- Multilamellar vesicles (MLVs) of HSPC (Mw=762.10 g/mol, >99% purity, from Lipoid, Ludwigshafen, Germany) were prepared by hydrating the phospholipids in pure water at 62° C. (above the HSPC gel-to-liquid crystalline phase transition temperature, Tm=52.5° C.). The MLVs were downsized to form SUVs at a HSPC concentration of 30 mM, by stepwise extrusion through polycarbonate membranes from 400-nm to 50.-nm-pore-sizes at 65° C., using a
Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada. Water used (also for the SFB experiments) was purified (Milli-Q®Gradient A10 or Barnsted NanoPure systems) to 18.2 MΩ cm resistance with total organic content levels of 3-4 ppb (Milli-Q) or <ca.1 ppb (Barnstead). The pH of the water was 5.8 due to ions leached from glassware and dissolved atmospheric CO2. Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 65±3 nm in diameter. - Coating of Solid Mica Surfaces with Liposomes Prepared According to Example S1:
- Freshly cleaved, atomically smooth mica surfaces were incubated for 1.5-2 hours at 23±2° C., in a dispersion consisting of 360±10 μL of the HSPC-SUVs prepared as described in Example S1 in 10 ml water, whereon spontaneous adsorption of the liposomes took place. The Surfaces were then washed. (1 minutes gentle waving in excess of pure water or 5 minutes standing in pure water) to remove excess, non-adsorbed liposomes and rapidly mounted in the SFB (or taken for cryo-SEM) ensuring they remained wetted throughout. AFM (NT-MDT, Integra) topography images were taken in water in tapping mode using silicon nitride tips of 3 μm height, spring-Constant 0.5 N/m (Olympus, OMCL-TR800PSA). Cryo-SEM samples of HSPC-SUV-coated mica, prepared as described above, were frozen by plunging into liquid ethane and transferred to a
BAF 60 freeze fracture device (Bal-Tec AG, Liechtenstein). Water was sublimed at −80° C. for 2 hrs. Samples were rotary-shadowed with 3 nm Pt at an angle of 45°. Samples were transferred to an Ultra 55 SEM (Zeiss, Germany) using aVCT 100 vacuum-cryo transfer system (Bal-Tec AG, Liechtenstein) and observed at voltages of 2.5-5 kV. - It should be noted that as a comparative example, the experiment was repeated by using a mica surface on which a positively charged Chitosan polymer was adsorbed, thereby rendering the mica surface positively (instead of negatively) charged. HSPC liposomes did not adsorb onto such a surface.
- Characterization of HSPC-liposome coated Mica: Freshly cleaved mica surfaces were incubated in a dispersion of HSPC-SUV with a unimodal size distribution (diameter 65 nm), prepared as described herein, then rinsed and mounted in a surface force balance (SFB) filled with pure water. Similar liposome-coated mica surfaces were imaged using atomic force microscopy (AFM) and cryo-scanning-electron-microscopy (cryo-SEM), as shown in
FIG. 1 . The cryo-SEM image shows a honeycomb pattern characteristic of flattened close-packed spheres, overlaid by a loose, sparse layer of individual liposomes, which were not fully removed by the rinsing following the incubation. The AFM image (inset) shows that the liposomes are flattened by the adsorption from their unperturbed dispersion diameter to ca. 20 nm. - Lubrication:
- Normal and shear forces, Fn(D) and Fs(vs, D) respectively, between the interacting, liposome-coated mica surfaces as a function of their closest separation D and sliding velocity vs, were determined in the SFB. Fn(D) profiles are shown in
FIG. 2 . At large separations the forces decayed exponentially with D, and are attributed to double-layer electrostatic repulsions arising from the residual charge on the interacting surfaces. - The shear or frictional forces Fs transmitted between the surfaces as they were made to slide past each other were determined at different compressions (mean pressures P=(Fn/A) where A is the measured contact area, up to ca. 12 MPa); sliding amplitudes Δx0 (up to ca. 1 μm); and sliding velocities vs (5-2.103 nm/s). They were recorded directly as a series of shear-force vs. time traces as shown in
FIG. 3 . Fs values at all pressures, shear amplitudes and shear velocities studied were constant throughout a given trace, indicating the stability of the lubricating layers over the range of tested parameters. - The Fs vs. Fn results are summarized in
FIG. 4 . The frictional forces on a first approach of the surfaces, empty symbols in the inset toFIG. 4A , correspond to friction coefficients μ=(δFs/δFn) in the range μ=(2×10−3-5×10−4) as the normal pressure increases to ca. 6 MPa. These forces, however, are systematically much smaller, at similar pressures, on a second and subsequent compressions at a given contact point, as shown by the solid symbols in the mainFIG. 4A (and inset), becoming lower than the noise level of the SFB up to pressures of ca. 1 MPa. At higher loads the shear forces reveal extremely low friction coefficients, down to μ=2×10−5, as shown by the dashed lines inFIG. 4A , up to the highest mean pressures attained in this study, P=ca. 12 MPa. The dependence of Fs on vs is shown inFIG. 4B for different high pressures, indicating, within the scatter, little variation in friction over nearly 3 orders-of-magnitude in sliding velocities (5-2.103 nm/s). - The strong reproducibility of the friction, on multiple approaches at the same contact point suggests that the HSPC-SUVs retain their structural integrity up to the highest pressures tested, even under shear. The limiting separation at Dhw=21±2 nm at the highest compressions corresponds to a thickness of some 4 bilayers of the HSPC phospholipids, consistent with two essentially flattened SUV layers.
- In another experiment the interactions between a bare mica surface and a mica surface coated with SUV HSPC liposomes prepared in pure water (according to Example S1) was tested. In this experiment SUV-HSPC liposomes were adsorbed to a single mica sheet which was brought into contact with an atomically smooth mica sheet, while measuring the force as a function of the distance between the surfaces. Two different surface coverages were obtained due to a different washing technique after the adsorption procedure. A more vigorous wash which left large areas of bare mica—is referred as ‘b’, and a gentle wash procedure that lead to a dense surface is referred as ‘a’.
- This system showed, for high surface coverage, very good levels of lubrication, μ≈10−4, up to pressures of ca. 6 Mpa, and for the low surface coverage (namely after extensive washings) showed high friction at pressures higher than 1 MPa.
- The same process described above (S1/S2) was repeated with the modification that the liposomes were prepared in 150 mM NaNO3 (Fluka, >99.999% purity) rather than in pure water.
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 75±3 nm in diameter.
Coating of Solid Mica Surfaces with Liposomes Prepared by Example S3: - HSPC-SUV were adsorbed on atomically smooth mica surface by placing freshly cleaved mica in 10 ml 150 mM NaNO3 and then adding 360±10 μL of the liposome dispersion (of concentration of 30 mM) for 1.5-2 hours of incubation. Then mica surfaces were washed to remove excess, non-adsorbed liposomes by placing the adsorbed surfaces in a beaker filled with 150 mM NaNO3 for a few minutes along with a delicate shake motion. All preparations were done in a laminar hood to prevent contamination.
- As summarized in Table 1, good lubrication was obtained between two surfaces coated with liposomes prepared as above, with μ≈2×10−4-10−2 at pressures up to 60 atmospheres.
- Hydrogenated Soy phosphocholine (HSPC, Mw=762.10 g/mol, Tm 52.50° C., >99% purity) was purchased from Lipoid (Ludwigshafen, Germany). 1,2-ditetradecanoyl-3-trimethylammonium-propane (chloride salt) (DMTAP, Mw=590.361 g/mol) was purchased from Avanti Polar Lipids, Inc. (Alabaster, Ala. USA).
- A mixture of HSPC and DMTAP (in a 95:5 mole ratio) was dissolved in hot ethanol to a concentration of 0.45 w/v. This solution was injected into pure water at temperature of 62° C. (above the gel-to-liquid crystalline phase transition temperature, Tm, of HSPC, 52.5° C.) in order to hydrate the lipids and form a dispersion of multilamellar liposomes, MLV at final concentration of 30 mM phospholipids (PL). Water was treated with a Barnstead Nanopure system. The resistance of water was 18.2 MΩ cm with total organic compound (TOC)<ca.1 ppb (Barnstead). MLV were downsized to form small unilamellar vesicles (SUV), 65 nm in diameter, at a concentration of 15 mM, by stepwise extrusion through polycarbonate membranes starting with a 400-nm and ending with 50-nm-pore-size membrane, using a
Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada). - Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 75±3 nm in diameter.
- The zeta potential of liposomes in pure water was 36.5 mV.
Coating of Solid Mica Surfaces with Liposomes Prepared by Example S4: - Cryo-SEM image of a mica surface covered with SUV HSPC/DMTAP liposomes in pure water showed that liposome adsorbed on a mica surface in not close-packed coverage.
- Normal force measurements between two opposing layers of HSPC/DMTAP in water revealed increased long range repulsion starting from D=250±50 nm down to a hard wall separation of 10±2 nm. Normal force measurements between one mica surface covered with HSPC/DMTAP liposomes against bare mica show repulsion which starts from D=150±75 nm clown to a hard wall separation of 6±1 nm.
- On second approach to the same contact point a higher normal force was measured for the same surface separation D. In the HSPC/DMTAP vs. bare mica system, a jump out was observed.
- Shear measurements of 2 HSPC/DMTAP coated mica surfaces in pure water show no response to shear up to pressures of 25±6 atm. A shear trace test demonstrated the low Fs as P<˜30 atm. Shear measurements of 1 HSPC/DMTAP coated surface vs. bare mica in pure water showed rigid coupling already in pressures of ˜10 atm.
- Fs vs. Fn for 1 HSPC/DMTAP coated surface vs. bare mica gave effective friction coefficient of 0.035, and for two-HSPC/DMTAP coated surfaces gave effective friction coefficient of 0.0001 for the higher load region.
- The same process described above (S4) was repeated with the modification that the liposomes were prepared in 150 mM NaNO3 (Fluka, >99.999% purity) rather than in pure water using four dialysis steps at 4° C.
- Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Sizer (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 61.9 nm in diameter.
- The zeta potential of liposomes was 4.18 mV after replacing the external medium with 150 mM NaNO3.
- Coating of Solid Mica Surfaces with Liposomes Prepared by Example S5:
- HSPC/DMTAP SUV were adsorbed on atomically smooth mica surface by placing freshly cleaved mica in 10 ml 150 mM NaNO3 salt solution and then adding 720±20 μL of the liposome dispersion for 1 hour of incubation. After 1 hour the mica surfaces were placed in 400 ml beaker of 150 mM NaNO3 for 1-2 minutes in order to remove excess, non-adsorbed liposomes.
- Cryo-SEM samples (mica surfaces covered with HSPC:DMTAP 95:5 liposomes) were prepared as described above, with additional rinsing step by placing the sample in pure water for few seconds in order to remove salt. Samples were frozen by plunging into liquid ethane and transferred to a
BAF 60 freeze fracture device (BAl-Tec AG, Liechtenstein). Water was sublimed in theBAF 60 at a temperature of −100 degrees for 1 hour. Pt cover of the samples by rotary shadowing of 1.5 nm followed by 1.5 nm of Pt in an angle of 45 degrees. Samples were transferred to an Ultra 55 SEM (Zeiss, Germany) using aVCT 100 vacuum-cryo transfer system (Bal-Tec AG, Liechtenstein) and observed at voltages of 2.5 to 5 kV. Cryo-SEM imaging of the liposomes showed that the HSPC/DMTAP liposomes indeed adsorbed onto the mica to form a dense carpet on the surface. The liposomes did not fuse but remained separated from one another, where each liposome had a mean diameter of ca. 64 nm (in the range of 35 nm to 92 nm). - Normal force profiles between the two mica surfaces covered with HSPC/DMTAP liposomes immersed in 150 mM NaNO3 solution showed no interaction down to surface separation of 90±30 nm. Then, repulsion force evolves increasing rapidly as surfaces are forced to approach one another. At the highest normalized loads of 2 N/m corresponding to pressures of ca. 6 MPa the surfaces reached hard wall separation of'31±2 nm. On the second approach to the same contact point, a higher repulsion force was measured for a given surface separation D.
- The effective, friction coefficient μ=δFs/δFn was calculated to be in the range of μ=3×10−3-2×10−4 as the normal pressure increased to about 6 MPa.
- Hydrogenated Soy phosphocholine (HSPC, Mw=762.10 g/mol, Tm 52.50° C., >99% purity) was purchased from Lipoid (Ludwigshafen, Germany). 0.9145 gr HSPC were dissolved in hot ethanol to a concentration of 0.45 w/v. This solution was injected into pure water at temperature of 62° C. (above the gel-to-liquid crystalline phase transition temperature, Tm, of HSPC, 52.5° C.) in order to hydrate the lipids and form a 40 ml dispersion of multilamellar liposomes, MLV at final concentration of 30 mM phospholipids (PL). Water was treated with a Barnstead Nanopure system. The resistance of water was 18.2 MO cm with total organic compound (TOC)<ca.1 ppb (Barnstead). MLV HSPC mean radius size of 1.24±0.57 μm was measured with particle size analyzer LS 13 320 equipped with the PIDS unit which can determine particle size at the range of 40 nm to 2.0 mm (Beckman Coulter).
- Normal force measurements between mica surface covered with HSPC MLVs liposomes in opposing to a bare mica surface in pure water reveal repulsion starting from D=1250±250 nm. The measured normal force in the second approach to a contact point was lower then what was measured on the first approach to the point for a given surface separation D. Contact hard wall position value was found to be around 70 nm. However, during shear this value was reduced—after 12 minutes of shear the hard wall value was reduced by 3.5 nm.
- Shear force measurements between a mica surface covered with HSPC MLVs liposomes in opposing to a bare mica surface in pure water at different surface separation D and applied normal force (pressure) show that a similar shear force was measured during the first approach to a contact point and on during the second approach.
- From the plot of Fs vs. Fn the effective friction coefficient μ was deduced to be in the range of μ=7×10−3 to 5×10−4, for both first and second approaches as pressures are up to ˜30 atm.
- MLV-DSPC liposomes (DSPC, Mw=790.145 g/mol, Tm 55° C., >99% purity, from Lipoid, Ludwigshafen, Germany) were prepared by hydrating the phospholipids in pure water at around 65° C. (above the gel-to-liquid crystalline phase transition temperature). The MLVs were downsized to form SUVs at a final concentration of 15 mM, by stepwise extrusion through polycarbonate membranes from 400-nm to 50-nm-pore-sizes at 65° C., using a
Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada. Water used (also for the SFB experiments) was purified (Barnsted NanoPure systems or milli-Q gradient A10) to 18.2 MΩ cm resistance with total organic content levels of 3-4 ppb (Milli-Q) or <ca.1 ppb (Barnstead). The pH of the water was 5.8 due to ions leached from glassware and dissolved atmospheric CO2. Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Size (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 65±10 nm in diameter. The normal force profiles were similar in range and magnitude to those described for HSPC-SUV in example S1 above (e.g.FIG. 2 ). The shear traces and resulting load vs. friction data are shown inFIGS. 5A and 5B , revealing excellent lubrication up to high pressures (>100 atms). Cryo-SEM micrographs of the DSPC-SUV on mica revealed close-packed layers on the surface. - MLV-DPPC liposomes (DPPC, Mw=734.1, Tm 41.4° C., >99% purity, from Lipoid, Ludwigshafen, Germany) were prepared by hydrating the phospholipids in pure water at 55° C. (above the gel-to-liquid crystalline phase transition temperature). The MLVs were downsized to form SUVs at a final concentration of 15 mM, by stepwise extrusion through polycarbonate membranes from 400-nm to 50-nm-pore-sizes at around 60° C., using a
Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada. Water used (also for the SFB experiments) was purified (Barnsted NanoPure systems or milli-Q gradient A10) to 18.2 MO cm resistance with total organic content levels of 3-4 ppb (Milli-Q) or <ca.1 ppb (Barnstead). The pH of the water was 5.8 due to ions leached from glassware and dissolved atmospheric CO2. Liposomes were characterized for size distribution by dynamic light scattering using an ALV-NIBS High Performance Particle Size (Langen, Germany) at a scattering angle of 173°. Over 98% of the freshly-prepared liposomes were 65±10 nm in diameter. Normal force profiles on first approach set on at a range and of magnitude similar, though somewhat smaller, to those for HSPC-SUV (FIG. 2 ), and shear traces at some of these points revealed very low friction (CoF down to 2×10−4 or even lower) at pressures up to 120 atms (12 MPa). The distance of closest approach at these highest pressures and shear were in the range 10-15 nm. On subsequent approaches at a given contact point the pressures that could be applied, prior to higher friction setting on, were significantly lower. The overall picture therefore was that despite the optimal low-friction, high-pressure values, in view of the range of results, the DPPC-SUV liposomes on solid surfaces were designated good, level 3 (rather than excellent, level 5) lubricants, as explained following Table 1 for S11. - These results relate to good to excellent boundary lubrication of solid surfaces by two different SUV gel-phase liposomes additional to the HSPC, consisting of DPPC(S11), with Tm=41.4° C., and of DSPC(S10) which has a Tm=55° C.
FIGS. 5A and 5B show the friction traces and the friction vs. load plot for the DSPC-SUV liposome and indicate the very low friction coefficient even up to 100 or more atms, at around room temperature (Troom=25° C., clearly much lower than Tm). In addition, there are traces for the DSPC-SUV that show clearly that the friction after very long sliding—an hour or so—remains very low, indicating that wear is very low: this is a qualitatively new and very important indication, showing that even after thousands of back-and-forth cycles the lubricating layer retains its integrity and efficiency. - SUV HSPC/PEG liposome mixtures in water were prepared as a comparative example, since the PEG external head groups have an end-to-end radius which is larger than 1 nm (being 4 nm). The HSPC/PEG liposomes were prepared and characterized as described in Langmuir 21, 2560 (2005).
- Cryo-SEM images of mica surfaces covered with HSPC/PEG liposomes show liposomes indeed adsorbed onto mica surface. Normal force profiles between two SUV HSPC/PEG coated mica surfaces across pure water show repulsion from ˜100 nm. Hard wall of 10±4 nm was reached by increasing the normal load. At some contact points at higher pressures of more than ˜21 atm, the adsorbed layers were removed from the internal gap, and a surface separation of D=+0.8 nm.
- Shear traces show that Fs increase along with the rise in pressure such that for pressure of ˜25±5 atm., the two surfaces no longer slided one past the other but they move together in tandem so that no further sliding between them occurred. The effective friction coefficient up to that point was in the range of 0.05-0.03.
- SUV POPC liposomes in water were prepared as a comparative example, since the obtained liposome has a Tm which is smaller than the measuring temperature, being smaller than about 15° C. (being −3° C.). 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC, Mw=760.076 g/mol, Tm −3° C., >99% purity) was purchased from Lipoid (Ludwigshafen, Germany). 0.456 gr POPC were dissolved in hot ethanol to a concentration of 0.45 w/v. This solution was injected into pure water at temperature of 250° C. (above the gel-to-liquid crystalline phase transition temperature, Tm, of POPC, −3° C.) in order to hydrate the lipids and form a dispersion of multilamellar liposomes, MLV at final concentration of 30 mM phospholipids (PL). Water was treated with a Barnstead Nanopure system. The resistance of water was 18.2 MΩ cm with total organic compound (TOC)<ca.1 ppb (Barnstead). MLV were downsized to form small unilamellar vesicles (SUV), ca. 68 nm in diameter, by stepwise extrusion through polycarbonate membranes starting with a 400-nm and ending with 50-nm-pore-size membrane, using a
Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada). - Liposomes were characterized for size distribution by dynamic light scattering using Malvern Zetasizer—nano series (Malvern Instrument Limited—UK) at a scattering angle of 173°. 100% of the liposomes were 68.8 nm in diameter.
- Normal force measurements between two opposing layers of POPC in pure water revealed repulsion starting from D=100±20 nm down to a hard wall separation of 10.5±1 nm. Upon separation and reentering the contact point the normal force profile is shifted in the repulsion region such that for a given surface separation D, Fn/R is higher on the second approach then the first approach. A jump out from a distance of Dj=17.3±3.5 nm was observed while separating the two surfaces from contact. The surface tension Γ was deduced from the jump out separation distance to be Γ=6.1±3.1 mN/m both on first and second separation from the contact point.
- Shear measurements were preformed between two opposing adsorbed layers of POPC at different surface separation D and applied normal force (pressure). Traces show that the shear force is higher upon second approach to a contact point then the first approach. On first approach the friction force remains low for pressures values of P<˜25 atm; on second approach the corresponding pressure to reach such low friction force values are much lower P<˜10 atm.
- During shear, it occurred that the measured friction force increased dramatically from a low friction force that has a sliding trace shape, into a rigid coupling of the two surfaces of a triangular trace shape, which means the friction was so high that they were no longer sliding.
- From the plot of Fs vs. Fn it can be deduced that the effective friction coefficient μ for the first approach is μ=3×10−3, but from the second approach the friction coefficient increased to μ=1×10−1.
- The friction was measured between mica surfaces each coated with a layer of POPC SUVs (which, unlike the similarly-sized HSPC-SUVs, are in the liquid-crystalline phase at room temperature, Tm(POPC)=−3° C.). It was found that such layers provided poor lubrication (friction coefficients up to μ≈0.1) at pressures of just 1 MPa. Force profiles suggested that at higher pressures the POPC-SUVs had collapsed and were being partly squeezed out from between the surfaces, attributed to the lower rigidity (higher fluidity) of these liquid-crystalline-phase vesicles, resulting in a less stable phosphocholine lubricating layer at high pressures.
- Lipids.
- Table 1 describes the lipids (>98% pure) used in this experiment.
- Hyaluronic Acid (HA).
- A linear heteropolysaccharide with repeating 3-O-(β-D-glucuronido)-N-acetyl-D-glucosamine units linked by (β1-4) hexosaminidic bonds, sourced from rooster combs, having an average molecular weight of (1-4)×106 (Sigma) was dissolved in histidine buffer (HB) to a concentration of 5 mg/ml.
- Water.
- Water used was purified Barnsted NanoPure systems to 18.2 MΩ cm resistance with total organic content levels of <ca.1 ppb.
- Liposomes.
- Multilamellar vesicles (MLV) composed of pure Phosphatidylcholines (PCs): POPC, DMPC and HSPC, were prepared by hydrating the lipids in at least 5° C. above the lipid TM. To get small unilamellar vesicles (SUV, <100 nm), MLVs were downsized by stepwise extrusion through polycarbonate membranes starting with a 400-nm and ending with 50-nm-pore-size membrane, using a
Lipex 100 mL extruder system (Northern Lipids, Vancouver, Canada), heated at least 5° C. above the lipid TM. - The following liposomes suspensions were used: MLVs liposomes concentration was of 130±10 mM, SUVs liposomes concentration was of 35±5 mM.
- Cartilage.
- Articular cartilage from freshly slaughtered and healthy bovine was used for friction tests. Specimens of cartilage (approximately thickness of 3-4 mm) were removed from the surface using a scalpel. Samples were kept at −20° C. until used. For each test two samples were glued: one on the lower surface and the other on the upper surface. Size of the lower surface was ˜0.8 cm2 and size of the upper surface was 0.14±0.02 cm2. The cartilage samples were glued to their holders using a cyanoacrylate-based glue.
- Friction Testing.
- Friction testing was carried out using a CETR© tribometer, UMT model with high sensor which enables high normal loads. The system configuration was of a cartilage on a cartilage setup, in which two samples of bovine cartilage are immersed in HB, saline (0.9% w/v) or in synovial fluid (SF, obtained from the fresh bovine joints). The cartilage samples were subjected to relative sliding over a wide range of loads of 1 to 12 kg (10 to 120 N), equivalent to physiological pressures in joints (0.73±0.1 MPa to 8.75±1.25 MPa). The testing parameters were the following: Sliding velocity of 1 mm/sec, sliding amplitude of 1.5 mm and dwell time of 5 sec. Experiments were at room temperature (ca. 25±1 C)
- The static friction coefficient is obtained from the maximum value from the shear trace, and the kinetic friction coefficient is calculated as the average value at the sliding region. The data summaries are based on the mean of 2-3 independent experiments (i.e. 2-3 fresh pairs of cartilage surfaces) in each case, except for the synovial fluid control (1 experiment), and 40 back-and-forth cycles per measurement. The cartilage surfaces were incubated for 30 mins in the liposome solutions prior to friction measurements.
-
Phase transition temperature Short name Chemical name MW (Tm), ° C. POPC 1-palmitoyl-2-oleoyl- 760.1 −3 sn-glycero-3- phosphocholine DMPC 1,2-dimyristoyl-sn- 677.9 23.2 glycero-3- phosphocholine HSPC hydrogenated soybean 762.1 52.5 phosphocholine - The results of the lubrication experiments are shown in
FIGS. 6A-B and 7A-B. The trends of the friction data in the experiments with the liposomes were striking and very much in line with the earlier examples described in Tables 1 and 2 where the gel-phase liposomes were better lubricants at high pressures. At the lower pressures, around 2.2 MPa pressure (30N load), the dynamic friction coefficients of all three systems (DMPC-MLV, POPC-MLV and HSPC-MLV) were similar to each other, in the range CoF μ=0.032±0.007, with the DMPC-MLV at the lower part of this range and the POPC-MLV at the higher part of this range. At the highest pressures, around 8.8 MPa (which is comparable to the pressures in human hips and knees), the values of the friction coefficients diverge significantly: HSPC-MLV (gel-phase at the temperature of the measurements) now had significantly lower CoF μ≈0.02, compared with CoF μ≈0.04 for the DMPC-MLV (liquid-crystalline-phase at the temperature of the measurements) and μ≈0.085 for the POPC-MLV (liquid-crystalline-phase at the temperature of the measurements). - In the figures:
-
FIG. 1 : Cryo-SEM image of the HSPC-SUV adsorbed on freshly cleaved mica as described in Methods section; -
FIG. 2 : 2A: Normal force Fn vs. surface-separation D profiles between interacting HSPC-SUV coated mica surfaces. Profiles are normalized as Fn/R in the Derjaguin approximation, by the mica curvature radius R≈1 cm; the black line is the far-field force variation predicted by the DLVO model, (Fn(D)/R)=128πckBTκ−1 tan h2 (eψ0//kBT) exp (−κD), where c is the effective ion concentration, kB and T are Boltzmann's constant and the absolute temperature, κ−1 is the Debye screening length, e is the electronic charge and ψ0 the effective electrostatic potential, derived from the far-field profile, at the interacting surfaces (taken as the outer opposing liposome surfaces). For the best fit shown, κ−1=66 nm corresponding to c=2.3×10−5M of a 1:1 electrolyte, and ψ0=120 mV. The inset compares profiles on a first approach (full symbols) and second approach (corresponding empty symbols) from different contact positions. B: The flattened interference fringes shown correspond to a pressure of 10±1 MPa (arrow inFIG. 2A ); they provide a direct section through the contact zone (schematically shown on the right of 2B), and from such fringes the contact area A=πr2, and hence the mean pressure P=Fn/A, are evaluated; -
FIG. 3 : Typical shear (or friction) force Fs vs. time traces between HSPC-SUV coated mica surfaces taken directly from SFB; -
FIG. 4 : 4A: Friction forces Fs vs. applied loads Fn between two HSPC-SUV-coated mica surfaces, based on traces such as inFIG. 3. 4B : Friction forces Fs variation with sliding velocity for different compressions (◯ 74 atm; 94 atm; ▪ 107 atm; 118 atm) of HSPC-SUV coated mica surfaces showing little variation within the scatter over nearly 3 decades in vs. -
FIG. 5A : Shear traces between two mica surfaces coated with SUV-DSPC liposomes in pure water, measured using the surface force balance showing the shear force Fs vs. time. The traces demonstrate the shear force at different surface separations under various applied pressures. -
FIG. 5B : Friction force vs. the applied normal load between two SUV-DSPC coated mica surfaces, based on traces such as in 5A. The effective friction coefficient μ is calculated as μ=dFs/dFn directly from the graph, and reveal the excellent lubrication capability of such SUV-DSPC system. -
FIG. 6 : Dynamic (6A) and Static (6B) Friction coefficients vs. load (N) according to preferred embodiments of the invention for bovine articular cartilage surfaces following incubation in HSPC-MLV, DMPC-MLV, and POPC-MLV liposome solutions in histidine buffer. -
FIG. 7 : Dynamic and Static friction coefficients for different systems (both controls and with liposomes) for a 30N load (FIG. 7A ) and for a 120N load (FIG. 7B ) between sliding bovine cartilage surfaces according to preferred embodiments of the invention.
Claims (29)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/704,866 US20130142863A1 (en) | 2010-06-17 | 2011-06-16 | Phosphatidylcholine lipid liposomes as boundry lubricants in aqueous media |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35557310P | 2010-06-17 | 2010-06-17 | |
| US13/704,866 US20130142863A1 (en) | 2010-06-17 | 2011-06-16 | Phosphatidylcholine lipid liposomes as boundry lubricants in aqueous media |
| PCT/IL2011/000477 WO2011158237A1 (en) | 2010-06-17 | 2011-06-16 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IL2011/000477 A-371-Of-International WO2011158237A1 (en) | 2010-06-17 | 2011-06-16 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/809,816 Division US11541008B2 (en) | 2010-06-17 | 2020-03-05 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20130142863A1 true US20130142863A1 (en) | 2013-06-06 |
Family
ID=44630139
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/704,866 Abandoned US20130142863A1 (en) | 2010-06-17 | 2011-06-16 | Phosphatidylcholine lipid liposomes as boundry lubricants in aqueous media |
| US16/809,816 Active US11541008B2 (en) | 2010-06-17 | 2020-03-05 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
| US17/984,761 Active 2032-06-20 US12364662B2 (en) | 2010-06-17 | 2022-11-10 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US16/809,816 Active US11541008B2 (en) | 2010-06-17 | 2020-03-05 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
| US17/984,761 Active 2032-06-20 US12364662B2 (en) | 2010-06-17 | 2022-11-10 | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20130142863A1 (en) |
| EP (1) | EP2582406B1 (en) |
| BR (1) | BR112012032153A2 (en) |
| CA (1) | CA2803034A1 (en) |
| IL (1) | IL223518A (en) |
| WO (1) | WO2011158237A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111065423A (en) * | 2017-08-22 | 2020-04-24 | 莫比斯医疗有限公司 | Liposome formulations for joint lubrication |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015001564A1 (en) | 2013-07-04 | 2015-01-08 | Yeda Research And Development Co. Ltd. | Low friction hydrogels and hydrogel-containing composite materials |
| ES2894829T3 (en) * | 2014-06-15 | 2022-02-16 | Yeda Res & Dev | Surface treatment using water-soluble polymers and lipids/liposomes |
| IL243285A0 (en) | 2015-12-22 | 2016-04-21 | Yeda Res & Dev | Lipid analogs and liposomes comprising same |
| CN115569235B (en) * | 2022-06-29 | 2023-12-22 | 湖南工业大学 | Preparation method of hydrogel based on lipid lubrication |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304380A (en) * | 1989-11-09 | 1994-04-19 | Japan Tobacco Inc. | Glucosamine derivative and liposome containing the same as membrane constituent |
| US20030139344A1 (en) * | 2001-11-19 | 2003-07-24 | Mien-Chie Hung | Antitumor activity of Bok |
| US20040067196A1 (en) * | 2000-10-11 | 2004-04-08 | Brunke Karen J. | Targeted therapeutic lipid constructs |
| US20050069576A1 (en) * | 2003-09-25 | 2005-03-31 | Robert Mills | Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same |
| US20050123593A1 (en) * | 2001-06-25 | 2005-06-09 | Jonathan Thompson | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| US20050164981A1 (en) * | 2000-05-11 | 2005-07-28 | Burdick Julie-Anne M. | Biological lubricant composition and method of applying lubricant composition |
| US20070026061A1 (en) * | 2005-05-25 | 2007-02-01 | Nahid Ali | Liposomal formulation and use thereof |
| US7749485B2 (en) * | 2004-06-03 | 2010-07-06 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
| US20110171288A1 (en) * | 2008-02-20 | 2011-07-14 | Fatemeh Mohammadi | Topical compositions and methods for whitening skin |
| US20120183596A1 (en) * | 2000-06-09 | 2012-07-19 | Regulon, Inc. | Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes |
| US8263118B2 (en) * | 2005-05-20 | 2012-09-11 | Fidia Farmaceutici S.P.A. | Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof |
| US20130323165A1 (en) * | 2010-03-08 | 2013-12-05 | Northeastern University | Magnetic Nanoplatforms for Theranostic and Multi-Modal Imaging Applications |
| US8895054B2 (en) * | 2006-09-28 | 2014-11-25 | Technion Research And Development Foundation Ltd. | Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0386923A1 (en) * | 1989-03-09 | 1990-09-12 | Exxon Chemical Patents Inc. | Hydrogenated lecithin for friction and flow properties |
| US5688496A (en) * | 1994-08-31 | 1997-11-18 | Mona Industries, Inc | Silicone modified phospholipid compositions |
| JP2007524604A (en) * | 2003-03-31 | 2007-08-30 | アルザ・コーポレーシヨン | Lipid particles having an asymmetric lipid coating and method for producing the same |
| GB2426703B (en) * | 2005-05-31 | 2007-09-19 | Malvern Cosmeceutics Ltd | Compositions |
-
2011
- 2011-06-16 US US13/704,866 patent/US20130142863A1/en not_active Abandoned
- 2011-06-16 BR BR112012032153A patent/BR112012032153A2/en not_active IP Right Cessation
- 2011-06-16 EP EP11743371.4A patent/EP2582406B1/en active Active
- 2011-06-16 CA CA2803034A patent/CA2803034A1/en not_active Abandoned
- 2011-06-16 WO PCT/IL2011/000477 patent/WO2011158237A1/en not_active Ceased
-
2012
- 2012-12-09 IL IL223518A patent/IL223518A/en active IP Right Grant
-
2020
- 2020-03-05 US US16/809,816 patent/US11541008B2/en active Active
-
2022
- 2022-11-10 US US17/984,761 patent/US12364662B2/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304380A (en) * | 1989-11-09 | 1994-04-19 | Japan Tobacco Inc. | Glucosamine derivative and liposome containing the same as membrane constituent |
| US20050164981A1 (en) * | 2000-05-11 | 2005-07-28 | Burdick Julie-Anne M. | Biological lubricant composition and method of applying lubricant composition |
| US20120183596A1 (en) * | 2000-06-09 | 2012-07-19 | Regulon, Inc. | Encapsulation of Plasmid DNA (Lipogenes) and Therapeutic Agents with Nuclear Localization Signal/Fusogenic Peptide Conjugates into Targeted Liposome Complexes |
| US20040067196A1 (en) * | 2000-10-11 | 2004-04-08 | Brunke Karen J. | Targeted therapeutic lipid constructs |
| US20050123593A1 (en) * | 2001-06-25 | 2005-06-09 | Jonathan Thompson | Liposomal encapsulation of glycosaminoglycans for the treatment of arthritic joints |
| US20030139344A1 (en) * | 2001-11-19 | 2003-07-24 | Mien-Chie Hung | Antitumor activity of Bok |
| US20050069576A1 (en) * | 2003-09-25 | 2005-03-31 | Robert Mills | Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same |
| US7749485B2 (en) * | 2004-06-03 | 2010-07-06 | Bracco Research S.A. | Liposomal assembly for therapeutic and/or diagnostic use |
| US8263118B2 (en) * | 2005-05-20 | 2012-09-11 | Fidia Farmaceutici S.P.A. | Bioresorbable fillers constituted by phospholipid liposomes and hyaluronic acid and/or the derivatives thereof |
| US20070026061A1 (en) * | 2005-05-25 | 2007-02-01 | Nahid Ali | Liposomal formulation and use thereof |
| US8895054B2 (en) * | 2006-09-28 | 2014-11-25 | Technion Research And Development Foundation Ltd. | Methods for joint lubrication and cartilage wear prevention making use of glycerophospholipids |
| US20110171288A1 (en) * | 2008-02-20 | 2011-07-14 | Fatemeh Mohammadi | Topical compositions and methods for whitening skin |
| US20130323165A1 (en) * | 2010-03-08 | 2013-12-05 | Northeastern University | Magnetic Nanoplatforms for Theranostic and Multi-Modal Imaging Applications |
Non-Patent Citations (2)
| Title |
|---|
| Bard et al (Clin. and Experimental Rheumatology, vol. 3, pp. 237-242, 1985) * |
| Bard, D.R., et al Bard et al (Clin. and Experimental Rheumatology, vol. 1, pp. 113-117, 1983) * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111065423A (en) * | 2017-08-22 | 2020-04-24 | 莫比斯医疗有限公司 | Liposome formulations for joint lubrication |
| US11123293B2 (en) | 2017-08-22 | 2021-09-21 | Moebius Medical Ltd. | Liposomal formulation for joint lubrication |
| CN111065423B (en) * | 2017-08-22 | 2022-04-12 | 莫比斯医疗有限公司 | Liposome formulations for joint lubrication |
| US12214077B2 (en) | 2017-08-22 | 2025-02-04 | Moebius Medical Ltd. | Liposomal formulation for joint lubrication |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2582406B1 (en) | 2018-03-14 |
| IL223518A (en) | 2016-07-31 |
| WO2011158237A1 (en) | 2011-12-22 |
| CA2803034A1 (en) | 2011-12-22 |
| BR112012032153A2 (en) | 2017-08-08 |
| US12364662B2 (en) | 2025-07-22 |
| US20230080018A1 (en) | 2023-03-16 |
| US11541008B2 (en) | 2023-01-03 |
| US20200338001A1 (en) | 2020-10-29 |
| EP2582406A1 (en) | 2013-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12364662B2 (en) | Phosphatidylcholine lipid liposomes as boundary lubricants in aqueous media | |
| EP2079442B1 (en) | Use of glycerophospholipids for joint lubrication | |
| Jahn et al. | Hydration lubrication: the macromolecular domain | |
| Sivan et al. | Liposomes act as effective biolubricants for friction reduction in human synovial joints | |
| Goldberg et al. | Liposomes as lubricants: Beyond drug delivery | |
| EP3758681B1 (en) | A lipid-based coating composition, and an object having a lipid-based coating | |
| CN107073031A (en) | Utilize the surface treatment of water-soluble polymer and lipid/liposome | |
| JP7383759B2 (en) | Liposomal formulations for joint lubrication | |
| Cao et al. | Boundary lubrication, hemifusion, and self-healing of binary saturated and monounsaturated phosphatidylcholine Mixtures⧫ | |
| Wang et al. | Investigation of the lubrication properties and synergistic interaction of biocompatible liposome-polymer complexes applicable to artificial joints | |
| Duan et al. | Insight into the tribological behavior of liposomes in artificial joints | |
| TWI782181B (en) | Liposomal formulation for joint lubrication | |
| Pawlak et al. | Natural Joints: Biological boundary layered lubrication of phospholipid bilayers | |
| EA042384B1 (en) | LIPOSOMAL COMPOSITION TO PROVIDE A JOINT LUBRICANT | |
| Shi | Investigations of cartilage lubricity and interactions between carbon nanotubes and phospholipid bilayers | |
| CA2340975A1 (en) | Synthetic tear fluid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEIN, JACOB;GOLDBERG, RONIT;BARENHOLTZ, YECHEZKEL;AND OTHERS;SIGNING DATES FROM 20121223 TO 20130123;REEL/FRAME:029782/0787 |
|
| AS | Assignment |
Owner name: YEDA RESEARCH AND DEVELOPMENT CO., LTD., ISRAEL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KLEIN, JACOB;GOLDBERG, RONIT;REEL/FRAME:029788/0013 Effective date: 20121223 Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNORS FOR THE ASSIGNMENT RECORDED ON FEBRUARY 8, 2013 PREVIOUSLY RECORDED ON REEL 029782 FRAME 0787. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNORS ASSIGNED ALL RIGHTS TO ASSIGNEE AS IDENTIFIED;ASSIGNORS:BARENHOLTZ, YECHEZKEL;SCHROEDER, AVI;SIGNING DATES FROM 20121226 TO 20130123;REEL/FRAME:029787/0961 |
|
| STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
| STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |